Page last updated: 2024-11-05

megestrol acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Megestrol acetate is a synthetic progestin that is used primarily for the treatment of breast cancer and appetite stimulation in patients with cancer-related cachexia. It is also used off-label to treat endometriosis and uterine fibroids. Megestrol acetate acts as an antagonist of the progesterone receptor, blocking the effects of the hormone. In breast cancer, it is used to treat both early and advanced disease, often in combination with other therapies. In cancer-related cachexia, it stimulates appetite and weight gain by acting on the hypothalamus, a region of the brain that regulates appetite. The synthesis of megestrol acetate involves multiple steps starting with a steroid precursor, followed by modifications and reactions to produce the final compound. Research on megestrol acetate continues to explore its mechanisms of action, potential side effects, and its use in various conditions.'

anisatin: RN given refers to cpd without isomeric designation; also see 2-oxo-6-deoxyneoanisatin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

anisatin : A sesquiterpene lactone with formula C15H20O8. It is a neurotoxic natural product found in plants of the family Illiciaceae. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID115121
CHEMBL ID220362
SCHEMBL ID638960
MeSH IDM0028721
PubMed CID11683
CHEMBL ID1201139
CHEBI ID6723
SCHEMBL ID745
MeSH IDM0028721

Synonyms (198)

Synonym
spiro(6h-4,9a-methanocyclopent(d)oxocin-6,3'-oxetane)-2,2'(1h)-dione, hexahydro-1,5,6a,7-tetrahydroxy-5,9-dimethyl-, (1r-(1alpha,4beta,5beta,6beta,6abeta,7beta,9alpha,9abeta))-
(-)-anisatin
spiro(6h-4,9a-methanocyclopent(d)oxocin-6,3'-oxetane)-2,2'(1h)-dione, hexahydro-1,5,6a,7-tetrahydroxy-5,9-dimethyl-, (1r,3's,4r,5r,6ar,7r,9r,9as)-
spiro(6h-4,9a-methanocyclopent(d)oxocin-6,3'-oxetane)-2,2'(1h)-dione, 4a-beta,5,6a,7,8,9-hexahydro-5,9a-dimethyl-1-alpha,5-beta,6a-beta,7-beta-tetrahydroxy-
anisatin
5230-87-5
aniasatin
CHEMBL220362
w9k8802fzl ,
unii-w9k8802fzl
4a.beta.,5,6a,7,8,9-hexahydro-1.alpha.,5.beta.,6a.beta.,7.beta.-tetrahydroxy-5,9.alpha.-dimethylspiro(6h-4,9a-methanocyclopent(d)oxocin-6,3'-oxetane)-2,2'(1h)-dione
SCHEMBL638960
DTXSID6058396
bdbm50476092
(1s,2r,4r,5r,6s,7r,8r,11r)-4,5,7,11-tetrahydroxy-2,7-dimethylspiro[9-oxatricyclo[6.3.1.01,5]dodecane-6,3'-oxetane]-2',10-dione
Q2850134
CS-0182027
HY-N9506
AKOS040734796
megestrol acetole
megestrol acetate [usan:usp]
unii-tj2m0fr8es
tj2m0fr8es ,
MLS001074091 ,
AB00383046-13
AB00383046-15
AB00383046-14
BRD-K19507340-001-03-1
pregna-4,6-diene-3,20-dione, 17-(acetyloxy)-6-methyl-
MLS000028633 ,
smr000058691
LMST02030118
17alpha-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
NIA ,
megeron
nsc-71423
megace
17.alpha.-acetoxy-6-methylpregna-4,20-dione
bdh 1298
17.alpha.-acetoxy-6-dehydro-6-methylprogesterone
17-acetoxy-6-methylpregna-4,20-dione
pregna-4,20-dione, 17-hydroxy-6-methyl-, acetate
magestin
ovaban
ovarid
sc 10363
wln: l e5 b666 ov ku mutj a1 e1 fv1 fov1 l1
sc-10363 ,
6-methyl-6-dehydro-17.alpha.-acetoxyprogesterone
pregna-4,20-dione, 17-(acetyloxy)-6-methyl-
17-hydroxy-6-methylpregna-4,20-dione acetate
6-methyl-6-dehydro-17.alpha.-acetylprogesterone
6-dehydro-6-methyl-17.alpha.-acetoxyprogesterone
niagestin
6-methyl-17.alpha.-hydroxy-.delta.(sup 6)-progesterone acetate
17.alpha.-acetoxy-6-methyl-4,20-dione
volidan
nsc71423
megestryl acetate
cas-595-33-5
NCGC00016516-01
BSPBIO_000952
BPBIO1_001048
PRESTWICK3_000956
6-methyl-delta(sup 6)-dehydro-17-alpha-acetoxyprogesterone
6-dehydro-6-methyl-17-alpha-acetoxyprogesterone
17alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione
6-methyl-17-alpha-acetoxypregna-4,6-diene-3,20-dione
17-alpha-acetoxy-6-dehydro-6-methylprogesterone
megestat
sc10363
einecs 209-864-5
megestrol acetate [usan]
6-methyl-17-alpha-hydroxy-delta(sup 6)-progesterone acetate
6-methyl-6-dehydro-17-alpha-acetoxyprogesterone
ovaban (veterinary)
pregna-4,6-diene-3,20-dione, 17-hydroxy-6-methyl-, acetate
17-hydroxy-6-methylpregna-4,6-diene-3,20-dione acetate
megestrol acetole [progestins]
6-methyl-delta4,6-pregnadien-17alpha-ol-3,20-dione acetate
6-methyl-delta(sup 4,6)-pregnadien-17-alpha-ol-3,20-dione acetate
pallace
megace es
ccris 372
bdh1298
megestil
bdh-1298
CHEBI:6723 ,
megestin
AB00490013
595-33-5
C08151
megestrol acetate ,
MLS000759501
6-dehydro-6-methyl-17alpha-acetoxyprogesterone
6-methyl-6-dehydro-17alpha-acetoxyprogesterone
17-acetoxy-6-methylpregna-4,6-diene-3,20-dione
6-methyl-delta(sup 4,6)-pregnadien-17alpha-ol-3,20-dione acetate
6-methyl-17alpha-hydroxy-delta(sup 6)-progesterone acetate
17-hydroxy-6-methylpregna-4,6-diene-3,20-dione 17-acetate
17alpha-acetoxy-6-dehydro-6-methylprogesterone
6-methyl-17alpha-acetoxypregna-4,6-diene-3,20-dione
DB00351
6-methyl-delta(sup 6)-dehydro-17alpha-acetoxyprogesterone
megace (tn)
D00952
megestrol acetate (usp)
SPBIO_003101
PRESTWICK1_000956
PRESTWICK0_000956
PRESTWICK2_000956
NCGC00024196-03
6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
acetate, megestrol
maygace
HMS2090N04
HMS2051I20
[(8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1h-cyclopenta[a]phenanthren-17-yl] acetate
CHEMBL1201139
megestrol 17.alpha.-acetate
megesterol acetate
17alpha-acetoxy-6-methyl-4,6-pregnadiene-3,20-dione
HMS1570P14
A832354
17-(acetyloxy)-6-methylpregna-4,6-diene-3,20-dione
HMS2097P14
tox21_302360
dtxsid9040683 ,
NCGC00255456-01
dtxcid7020683
MLS001424055
tox21_110469
HMS2235D16
CCG-100899
BCP9000904
BCPP000168
(8xi,9xi,10xi,13xi,14xi)-6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate
megestrol acetate [who-ip]
6-methyl-3,20-dioxopregna-4,6-dien-17-yl acetate [who-ip]
medroxyprogesterone acetate impurity g [ep impurity]
megestrol acetate [usp monograph]
megestrol acetate [green book]
medroxyprogesterone acetate impurity g [who-ip]
megestrol acetate [vandf]
megestrol acetate [who-dd]
megestrol acetate [mi]
megestrol acetate [ep monograph]
megestrol acetate [orange book]
megestrol acetate [usp-rs]
megestrol acetate [mart.]
S1304
AKOS015894927
HY-13676
CS-2065
RQZAXGRLVPAYTJ-GQFGMJRRSA-N
NC00149
SCHEMBL745
tox21_110469_1
NCGC00024196-05
megestrolacetate
Q-201346
(8r,9s,10r,13s,14s,17r)-17-acetyl-6,10,13-trimethyl-3-oxo-2,3,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl acetate
AC-24570
AB00383046_16
OPERA_ID_1511
megestrol acetate, vetranal(tm), analytical standard
megestrol acetate, united states pharmacopeia (usp) reference standard
megestrol acetate, european pharmacopoeia (ep) reference standard
megestrol acetate, analytical standard, for drug analysis
megesgtrol acetate, pharmaceutical secondary standard; certified reference material
megestrol acetate for peak identification, european pharmacopoeia (ep) reference standard
megestrol acetate for system suitability, european pharmacopoeia (ep) reference standard
megestrol-17-acetate
sr-01000000258
SR-01000000258-4
HMS3714P14
par-100,2
mfcd00056470
megestrol-17-acetate 100 microg/ml in acetonitrile
AS-13384
Q6808975
megestrol-acetate
D91560
EN300-7480847
(1r,3as,3br,9ar,9bs,11as)-1-acetyl-5,9a,11a-trimethyl-7-oxo-1h,2h,3h,3ah,3bh,7h,8h,9h,9ah,9bh,10h,11h,11ah-cyclopenta[a]phenanthren-1-yl acetate
medroxyprogesterone acetate impurity g (ep impurity)
6-dehydro-6-methyl-17 alpha-acetoxyprogesterone
megestrol acetate (usp-rs)
ovaban tablets 20 mg, ovaban tablets 5 mg
megestrol acetate (usp monograph)
megestrol acetate (mart.)
medroxyprogesterone acetate impurity g
megestol
megestrol 17alpha-acetate
megestrol acetate (ep monograph)
megestrol acetate (usan:usp)
6-methyl-delta-4,6-pregnadien-17 alpha-ol-3,20-dione acetate
17 alpha-acetoxy-6-methylpregna-4,6-diene-3,20-dione

Research Excerpts

Overview

Megestrol acetate (MA) is a progestational agent for the treatment of metastatic breast cancer and endometrial cancer. It is an effective treatment for improving appetite and increasing body weight in patients with cancer-associated anorexia.

ExcerptReferenceRelevance
"Megestrol acetate is a synthetic progestogen used to treat some cancers and cancer-associated cachexia, but its potential interactions with other drugs are not well known. "( Megestrol acetate is a specific inducer of CYP3A4 mediated by human pregnane X receptor.
Chen, Y; Nie, D; Nie, JZ; Tang, Y; Zhang, Y, 2021
)
3.51
"Megestrol acetate (1) is a well-known progestin."( Megestrol acetate induced proliferation and differentiation of osteoblastic MC3T3-E1 cells: A drug repurposing approach.
Badran, SA; Choudhary, MI; Fayyaz, S; Taj, B, 2020
)
2.72
"Megestrol acetate is a frequently used drug in endometrial cancer patients."( Pterostilbene, a natural phenolic compound, synergizes the antineoplastic effects of megestrol acetate in endometrial cancer.
Dellinger, TH; Finlay, J; Glackin, CA; Han, ES; Lowe, G; Roberts, CM; Wen, W, 2017
)
1.4
"Megestrol acetate (MA) is a synthetic progestin that is widely used to increase appetite and weight in various clinical settings."( The effects of megestrol acetate on nutrition, inflammation and quality of life in elderly haemodialysis patients.
Chen, J; Chen, L; He, D; Xu, Y; Zhang, T; Zheng, Z, 2019
)
1.59
"Megestrol acetate (MA) is a progestational agent for the treatment of metastatic breast cancer and endometrial cancer. "( Primary symptomatic adrenal insufficiency induced by megestrol acetate.
Delitala, AP; Delitala, G; Fanciulli, G; Maioli, M; Piga, G, 2013
)
2.08
"Megestrol acetate (MA) is an appetite stimulant with efficacy in promoting weight gain in adults with cancer-associated anorexia-cachexia. "( A randomized, double-blind, placebo-controlled clinical trial of megestrol acetate as an appetite stimulant in children with weight loss due to cancer and/or cancer therapy.
Baker, TJ; Casey, LM; Cuvelier, GD; Distefano, DS; Dix, DB; Lambert, PJ; Mychajlunow, BA; Peddie, EF; Romanick, MA; Wardle, MG; Wilson, BA, 2014
)
2.08
"Megestrol acetate is an effective treatment for improving appetite and increasing body weight in patients with cancer-associated anorexia. "( Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state.
Cho, JY; Jang, IJ; Jang, K; Kim, SE; Lee, H; Lim, KS; Yoon, S; Yoon, SH; Yu, KS, 2014
)
2.13
"Megestrol acetate (MA) is a steroid origin medicine often used for control of cachexia in oncologic palliative care. "( Can megestrol acetate induce thrombosis in advanced oncology patients receiving chemotherapy?
Demir, G; Koksal, UI; Okutur, K; Ordu, C; Pilanci, KN; Saglam, S; Tecimer, C, 2014
)
2.4
"Megestrol acetate is a semi-synthetic progestational steroid that was originally used as a therapeutic modality for metastatic breast and endometrial cancers. "( Treating malnutrition with megestrol acetate: literature review and review of our experience.
Karcic, E; Morley, JE; Philpot, C, 2002
)
2.05
"Megestrol acetate (MA) is a progestational agent, currently known as one of the most effective appetite stimulants in patients suffering from cancer anorexia/cachexia syndrome. "( Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.
Adam, Z; Salajka, F; Tomíska, M; Tomisková, M; Vorlícek, J, 2003
)
2
"Megestrol acetate (MA) is a progestogen that has been demonstrated to increase appetite and weight in patients with cancer or acquired immunodeficiency syndrome."( Treatment of anorexia and malnutrition in peritoneal dialysis patients with megestrol acetate.
Aguilera, A; Bajo, MA; Costero, O; del Peso, G; Gil, F; Hevia, C; Ros, S; Selgas, R, 2004
)
1.27
"Megestrol acetate (MA) is a synthetic progestin commonly used to promote weight gain in malnourished older individuals. "( Effects of megestrol acetate on pituitary function and end-organ hormone secretion: a post hoc analysis of serum samples from a 12-week study in healthy older men.
Bodenner, DL; Evans, WJ; Lambert, CP; Liu, H; Medhi, M; Sullivan, DH, 2005
)
2.16
"Megestrol acetate (MA) is a progestational agent used for palliation of breast and endometrial cancer. "( High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate.
Chidakel, AR; Fleckman, AM; Homel, P; Schappert, JW; Schlosser, JR; Zweig, SB, 2006
)
2
"Megestrol acetate (MA) is a progestin widely used to treat weight loss and cachexia in patients suffering from AIDS or cancer. "( A retrospective study of the association between megestrol acetate administration and mortality among nursing home residents with clinically significant weight loss.
Bodenner, D; Hughes, T; Redman, C; Riggs, AT; Spencer, T; Strunk, B, 2007
)
2.04
"Megestrol acetate is a synthetic progestin that has been used since the 1970s for the treatment of advanced cancer and subsequently to treat anorexia, cachexia and weight loss in AIDS patients. "( Megestrol acetate-induced adrenal insufficiency.
Carnero López, B; Carrasco Alvarez, JA; Fernández Pérez, I; Gentil González, M; González Villarroel, P; Páramo, C; Vázquez Tuñas, ML, 2008
)
3.23
"Megestrol acetate is an effective treatment for some patients with AIDS-related anorexia and cachexia."( Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia.
Von Roenn, JH, 1994
)
1.33
"Megestrol acetate is a synthetic progestin that has been used for reversing anorexia in adult cancer."( Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours.
Azcona, C; Castro, L; Crespo, E; Jiménez, M; Sierrasesúmaga, L, 1996
)
2.46
"Megestrol acetate therapy is a powerful appetite stimulant which led to weight gain, composed of both fat mass and fat-free mass. "( Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumours.
Azcona, C; Castro, L; Crespo, E; Jiménez, M; Sierrasesúmaga, L, 1996
)
3.18
"Megestrol acetate is an effective treatment for advanced breast cancer in older women when used either as first- or second-line treatment."( A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer.
Blackledge, GR; Earl, H; Keen, C; Spooner, D; Stuart, NS; Taylor, AR; Tyrell, C; Warwick, J; Webster, DJ, 1996
)
1.26
"Megestrol acetate is a synthetic analog of progesterone. "( Megestrol acetate as a biomodulator.
Chang, AY, 1998
)
3.19
"Megestrol acetate (MA) is a synthetic progestin with reported activity in both hormone-sensitive and hormone-refractory prostate carcinoma (HRPC). "( A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
Conaway, M; Dawson, NA; Halabi, S; Lake, D; Small, EJ; Vogelzang, NJ; Winer, EP, 2000
)
1.99
"Megestrol acetate (MA) is an appetite-stimulating drug used to treat cachexia of chronic diseases."( Megestrol acetate increases short-term food intake in zinc-deficient rats.
Browning, JD; MacDonald, RS; Williamson, PS, 2002
)
2.48
"Megestrol acetate (MA) is a synthetic, orally active derivative of the naturally occurring hormone progesterone. "( Megestrol acetate to correct the nutritional status in an adolescent with growth hormone deficiency: Increase of appetite and body weight but only by increase of body water and fat mass followed by profound cortisol and testosterone depletion.
Freudenberg, S; Haas, RJ; Schmid, I; Schmitt, M; Schuster, F; Stachel, DK,
)
3.02
"Megestrol acetate (MA) is a progesterone frequently used for treating human immunodeficiency virus (HIV)-associated anorexia-cachexia."( Treatment with megestrol acetate improves human immunodeficiency virus-associated immune thrombocytopenia.
Gomez, F; Lopez, R; Rivera, C; Ruiz, P, 2002
)
1.39
"Megestrol acetate is an effective, well-tolerated agent in previously untreated patients with advanced breast cancer."( Front-line hormonal therapy for patients with advanced breast cancer: a community oncology research program.
Anderson, S; Sigal, RB; Smalley, RV, 1990
)
1

Effects

Megestrol acetate (MA) has a longstanding history in the treatment of breast cancer. Recently it is being used less often due to the advent of newer agents.

Megestrol acetate (MA) has a longstanding history in the treatment of breast cancer, but recently it is being used less often due to the advent of newer agents. The majority of the weight gain is adipose tissue. Megestrolacetate has no role in prolonging OS in advanced treatment-naive HCC.

ExcerptReferenceRelevance
"Megestrol acetate (MA) has a longstanding history in the treatment of breast cancer, but recently it is being used less often due to the advent of newer agents."( Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.
Bines, J; Branco, LGP; Camacho, PG; Castro, TM; Costa, MEF; Dienstmann, R; Obadia, RM; Quintella, DC; Soares, FA, 2014
)
1.5
"Megestrol acetate has a role in the palliation of patients with progressive disease despite initial hormonal therapy."( Megestrol acetate in the treatment of metastatic carcinoma of the prostate.
Venner, P, 1992
)
2.45
"Megestrol acetate (MA) has a longstanding history in the treatment of breast cancer, but recently it is being used less often due to the advent of newer agents."( Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.
Bines, J; Branco, LGP; Camacho, PG; Castro, TM; Costa, MEF; Dienstmann, R; Obadia, RM; Quintella, DC; Soares, FA, 2014
)
1.5
"Megestrol acetate (MA) has been used to treat weight loss in pediatric patients with malignancies, cystic fibrosis and HIV/AIDS. "( Megestrol acetate improves weight gain in pediatric patients with chronic kidney disease.
Barletta, GM; Bunchman, TE; Cole, MR; Ferguson, KB; Gast, TR; Hobbs, DJ; Weismantel, DP, 2010
)
3.25
"Megestrol acetate has no role in prolonging OS in advanced treatment-naive HCC. "( Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma.
Chen, Y; Chow, PK; Findlay, M; Gandhi, M; Hoang, HH; Jin, MY; Lim, CH; Lobo, R; Machin, D; Nguyen, BD; Soo, KC; Tan, SB; Win, KM; Zhang, X, 2011
)
2.09
"Megestrol acetate (MA) has glucocorticoid activity and can induce significant secondary adrenal suppression. "( A low-dose adrenocorticotropin test reveals impaired adrenal function in cancer patients receiving megestrol acetate therapy.
Goldray, D; Inbar, MJ; Ron, IG; Soyfer, V; Weisman, Y, 2002
)
1.97
"Megestrol acetate (MA) has been used to stimulate weight gain in elderly populations with the majority of the gain being adipose tissue. "( Effects of testosterone replacement and/or resistance training on interleukin-6, tumor necrosis factor alpha, and leptin in elderly men ingesting megestrol acetate: a randomized controlled trial.
Evans, WJ; Lambert, CP; Sullivan, DH, 2003
)
1.96
"Megestrol acetate (MA) has been used to stimulate weight gain in elderly populations, with the majority of the weight gain being adipose tissue. "( Megestrol acetate-induced weight gain does not negatively affect blood lipids in elderly men: effects of resistance training and testosterone replacement.
Evans, WJ; Lambert, CP; Sullivan, DH, 2003
)
3.2
"Megestrol acetate, 800 mg/day, has been shown to increase appetite and food intake and to mitigate inflammation in cachectic AIDS and cancer patients, leading to weight gain, but it is also associated with side effects at this dose."( Megestrol acetate in a moderate dose for the treatment of malnutrition-inflammation complex in maintenance dialysis patients.
Ghossein, C; Kalantar-Zadeh, K; Liang, A; Rammohan, M, 2005
)
2.49
"Megestrol acetate has been found to increase appetite, food intake, and weight in randomized, placebo-controlled trials in patients with advanced malignancies and in patients with AIDS."( Treatment of anorexia with megestrol acetate.
Tchekmedyian, NS, 1993
)
1.3
"Megestrol acetate has been reported to improve appetite and quality of life and to decrease nausea and vomiting in patients with cancer anorexia/cachexia. "( Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
Ghosh, C; Jett, JR; Jung, SH; Kugler, JW; Kuross, SA; Loprinzi, CL; Mailliard, JA; Maksymiuk, AW; Owen, D; Rowland, KM; Schaefer, PL; Shaw, EG; Tschetter, LK; Washburn, JH; Webb, TA, 1996
)
1.96
"Megestrol acetate has been demonstrated to improve appetite and weight, independent of tumor response, when used in the treatment of metastatic breast cancer."( Anticachectic efficacy of megestrol acetate at different doses and versus placebo in patients with neoplastic cachexia.
Antón, I; Batiste, E; Bestit, I; Blanco, R; Boleda, M; Cirera, L; Giménez-Arnau, JM; Jolis, L; Morales, S; Seguí, MA; Vadell, C, 1998
)
1.32
"Megestrol acetate has gained acceptance as a way to promote weight gain in cachectic patients without significant adverse effects."( Adrenal insufficiency masquerading as sepsis in a patient with tetraparesis: a case report.
Glenn, MB; Lee, LW, 2000
)
1.03
"Megestrol acetate has a role in the palliation of patients with progressive disease despite initial hormonal therapy."( Megestrol acetate in the treatment of metastatic carcinoma of the prostate.
Venner, P, 1992
)
2.45
"Megestrol acetate has few side effects, and has the advantage of stimulating appetite and weight gain, a benefit in cancer patients."( Megestrol acetate: clinical experience.
Canetta, R; Kelley, S; Nicaise, C; Rozencweig, M; Schacter, L; Smaldone, L, 1989
)
2.34
"Megestrol acetate has been observed to produce weight gain in patients with hormone-sensitive tumors and has recently been noted to produce a similar degree of weight gain in those with hormone insensitive tumors."( Studies of high-dose megestrol acetate: potential applications in cachexia.
Aisner, J; Novak, M; Parnes, H; Tait, N; Tchekmedyian, NS, 1988
)
1.32
"Megestrol acetate has only limited efficacy in patients previously treated for prostatic cancer by hormonal manipulation."( Phase II study of megestrol acetate for metastatic carcinoma of the prostate.
Crombie, C; Dalley, D; Devine, R; Page, J; Raghavan, D; Rosen, M; Woods, R, 1987
)
1.33
"Megestrol acetate has been observed anecdotally to produce weight gain."( Appetite stimulation with megestrol acetate in cachectic cancer patients.
Aisner, J; Greco, FA; Moody, M; Tait, N; Tchekmedyian, NS, 1986
)
1.29

Actions

Megestrol acetate is probably the most commonly used progestational drug for the treatment of breast cancer. It may cause suppression of the pituitary-adrenal axis due to its affinity for the glucocorticoid receptor.

ExcerptReferenceRelevance
"Megestrol acetate did not suppress the secretion of pituitary sex hormones, but in 3 of 10 patients studied was found inhibition of ACTH secretion."( [Treatment of uraemic anorexia with megestrol acetate].
Burguera, V; Fernández Lucas, M; Marcén, R; Quereda, C; Rivera, M; Rodríguez Palomares, JR; Sosa, H; Teruel, JL, 2010
)
1.36
"Megestrol acetate can inhibit the growth of Ishikawa cells. "( Altered claudin-4 expression in progesterone-treated endometrial adenocarcinoma cell line Ishikawa.
Cui-Ping, F; Hua, L; Hua-Jun, L; Xiao-Yu, P; Ya-Nan, W; Yan, J, 2012
)
1.82
"Megestrol acetate was shown to inhibit the growth of HepG2 cells in vitro in dose- and time-dependent manners with an IC (50) of 260 microm (24-h incubation). "( The effect of megestrol acetate on growth of HepG2 cells in vitro and in vivo.
Chow, PK; Zhang, K, 2004
)
2.13
"Megestrol acetate may cause suppression of the pituitary-adrenal axis due to the affinity of this compound for the glucocorticoid receptor."( Megestrol acetate-induced adrenal insufficiency.
Carnero López, B; Carrasco Alvarez, JA; Fernández Pérez, I; Gentil González, M; González Villarroel, P; Páramo, C; Vázquez Tuñas, ML, 2008
)
2.51
"Megestrol acetate, in part because of its oral formulation, is probably the most commonly used progestational drug for the treatment of breast cancer."( Overview of hormonal therapy in advanced breast cancer.
Canetta, R; Kelley, S; Nicaise, C; Rozencweig, M; Schacter, LP; Smaldone, L, 1990
)
1
"Megestrol acetate permits a lower dose of diethylstilbestrol, and thus lower toxicity."( Megestrol acetate: clinical experience.
Canetta, R; Kelley, S; Nicaise, C; Rozencweig, M; Schacter, L; Smaldone, L, 1989
)
2.34

Treatment

Megestrol acetate treatment of growth failure in pediatric human immunodeficiency virus disease is associated with weight gain, without affecting linear growth. Treatment with megestrolacetate results in rapid and significant improvement of symptoms in terminally ill patients at lower doses than previously reported.

ExcerptReferenceRelevance
"Megestrol acetate treatment significantly increased circulating free and total leptin concentrations in the cancer patients (P < 0.05)."( Circulating concentrations of "free" leptin in relation to fat mass and appetite in gastrointestinal cancer patients.
Kelly, A; McArdle, CS; McMillan, DC; Sattar, N; Wallace, AM, 2002
)
1.04
"Megestrol acetate-treated patients had a significantly greater mean maximum weight gain (p = 0.027) and appetite stimulation (p = 0.021) than did placebo-treated patients."( Randomized trials of megestrol acetate for AIDS-associated anorexia and cachexia.
Von Roenn, JH, 1994
)
1.33
"Megestrol acetate treatment of growth failure in pediatric human immunodeficiency virus disease is associated with weight gain, without affecting linear growth."( Megestrol acetate treatment of growth failure in children infected with human immunodeficiency virus.
Chadwick, EG; Clarick, RH; Hanekom, WA; Yogev, R, 1997
)
3.18
"Treatment with megestrol acetate results in a substained and very significant increase of the weight and body mass index in patients with AIDS related cachexia. "( [Megestrol in the treatment of AIDS associated cachexia. Evaluation by bioelectric impedance analysis of body composition].
Carnicero Bujarrabal, M; García Cortés, A; Menéndez Martínez, MA; Pérez Aznar, C; Pérez De Oteyza, C; Torres Léon, JM, 1998
)
0.65
"Treatment with megestrol acetate results in rapid and significant improvement of symptoms in terminally ill patients at lower doses than previously reported. "( Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study.
Belzile, M; Brown, B; Bruera, E; Dulude, H; Ernst, S; Gallant, G; Hagen, N; Hanson, J; Spachynski, K; Summers, N, 1998
)
0.99
"Treatment with megestrol acetate caused a non-significant reduction in serum estradiol (mean reduction of 19%, 0.05 less than P less than 0.1) but significant reductions in serum estrone (mean reduction of 20%, P less than 0.02) and serum estrone sulfate (mean reduction of 54%, P less than 0.005) compared to treatment with medroxyprogesterone acetate."( Influence of progestins on serum hormone levels in postmenopausal women with advanced breast cancer--II. A differential effect of megestrol acetate and medroxyprogesterone acetate on serum estrone sulfate and sex hormone binding globulin.
Lundgren, S; Lønning, PE, 1990
)
0.82

Toxicity

Megestrol acetate silicone vaginal ring is an effective and safe option of contraceptives. Megestrolacetate (MA) is neither safe nor effective for stimulating appetite in malnourished nursing home residents.

ExcerptReferenceRelevance
" Occurrence of adverse events, drug discontinuation, new AIDS-defining conditions, or CD4+ T lymphocyte changes were not statistically significantly different among arms."( The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. The DATRI 004 Study Group. Division of AIDS Treatment Research Initiative.
Egorin, MJ; Enama, ME; Galetto, G; Li, N; Mayers, J; Timpone, JG; Wright, DJ, 1997
)
0.53
" The purpose of this study is to evaluate the feasibility of supportive treatment with megestrol acetate (MA) in our weight-losing cancer patients increasingly experiencing anorexia, smell, taste, and weight loss due to the additive adverse effects of RT +/- chemotherapy and how MA changes the additive role of the severity of RT reactions on such patients."( Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy.
Erkisi, M; Erkurt, E; Tunali, C, 2000
)
0.53
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" However, the well-publicized adverse reports about these medications in acquired immunodeficiency syndrome (AIDS) and in the cancer population has led to some concern and much subsequent discussion over the safety of these medications being used in geriatric population."( Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.
Lovitt, S; Schuster, MW; Yeh, SS, 2007
)
0.34
"54%, the incidence of adverse events 11."( [Clinical efficacy and safety of megestrol acetate vaginal ring].
Huang, ZR; Qian, JF; Shen, YW; Zhu, XY, 2013
)
0.67
"Megestrol acetate silicone vaginal ring is an effective and safe option of contraceptives."( [Clinical efficacy and safety of megestrol acetate vaginal ring].
Huang, ZR; Qian, JF; Shen, YW; Zhu, XY, 2013
)
2.11
"Hysteroscopic resection of hyperplastic and/or cancer areas before high dosage progestin therapy seems to be a safe and effective approach in the management of ACH and in patients with early EC who wish to preserve fertility."( Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
Bergamini, A; Candiani, M; Colombo, G; De Marzi, P; Luchini, S; Mangili, G; Petrone, M; Taccagni, GL,
)
0.13
" Safety outcomes examined included adverse events (AEs) and deaths."( The Efficacy and Safety of Megestrol Acetate in Protein-Energy Wasting due to Chronic Kidney Disease: A Systematic Review.
Giles-Smith, L; Nadurak, S; Orsulak, C; Tangri, N; Wazny, LD, 2016
)
0.73
" Megestrol acetate (MA) is neither safe nor effective for stimulating appetite in malnourished nursing home residents."( Clinical Inquiry: Is megestrol acetate safe and effective for malnourished nursing home residents?
Millar, J; Nashelsky, J; Oberst-Walsh, L; Wen, FK, 2018
)
1.71
" Adverse events were commonly seen in the oncology population."( Propensity score-matching analysis comparing safety outcomes of appetite-stimulating medications in oncology patients.
Burger, A; Eladghm, N; Gamaleldin, A; Marie Gavioli, E; Vider, E, 2022
)
0.72

Pharmacokinetics

The pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood. This study was conducted to compare the safety and pharmacokinetics between the conventional formulation and a generic version of the advanced formulation containing nanocrystals.

ExcerptReferenceRelevance
"The developed UPLC-MS/MS method was successfully used for a pharmacokinetic study of oral (1 mg/kg) and intravenous (0."( Bioavailability and Pharmacokinetics of Anisatin in Mouse Blood by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Bao, X; Jiang, X; Ma, J; Wang, X; Zhou, Q, 2020
)
0.56
" The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role."( Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies.
Cacciari, N; Camaggi, CM; Martoni, A; Pannuti, F; Pavesi, L; Robustelli della Cuna, G; Silva, A; Strocchi, E; Tedeschi, M; Zamagni, C, 1995
)
0.53
" Statistical analysis of trough plasma level data indicated that steady-state levels of zidovudine and its glucuronide in plasma had been attained when pharmacokinetic assessments were made on days 4 and 17."( Pharmacokinetic interaction of megestrol acetate with zidovudine in human immunodeficiency virus-infected patients.
Pei, JC; Pike, IM; Van Harken, DR; Wagner, J, 1997
)
0.58
" The validated LC-MS/MS method was successfully applied for the evaluation of pharmacokinetic parameters of megestrol acetate after oral administration of a single dose 800 mg of megestrol acetate (Megace™) to five healthy Korean male volunteers under fed conditions."( Rapid and sensitive LC-MS/MS method for determination of megestrol acetate in human plasma: application to a human pharmacokinetic study.
Cho, YW; Jo, MH; Lee, KT; Noh, GJ; Park, JS; Park, MS; Ryu, JH; Seo, JH; Shim, WS, 2013
)
0.85
" Pharmacokinetic parameters were obtained by noncompartmental analysis."( Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Jin, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH; Park, HJ, 2015
)
0.66
"The pharmacokinetic characteristics and tolerability of the 2 megestrol acetate formulations are similar in fed volunteers and suggest no relevant difference in tolerability."( Tolerability and pharmacokinetics of two formulations of megestrol acetate under fed conditions in healthy volunteers.
Bae, KS; Bang, K; Choi, HY; Jin, S; Kim, MJ; Kim, YH; Lee, SH; Lim, HS; Noh, YH; Park, HJ, 2015
)
0.9
" The validated HPLC method was successfully applied to a pharmacokinetic study of W-1 in rats."( Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study in rats
Li, P; Liu, JY; Lou, YQ; Lu, C; Lu, YY; Ren, H; Wang, X; Wang, XW; Zhang, GL, 2015
)
0.42
" This study was conducted to compare the safety and pharmacokinetic characteristics between the conventional formulation of megestrol acetate and a generic version of the advanced formulation containing nanocrystals."( Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
Chae, DW; Guk, J; Park, C; Park, K; Son, H, 2016
)
0.9
" Primary pharmacokinetic parameters were Cmax and AUClast of the test and reference formulations of megestrol acetate."( Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
Chae, DW; Guk, J; Park, C; Park, K; Son, H, 2016
)
0.9
" However, the pharmacokinetic characteristics of megestrol acetate and its relation with food are not well understood."( Quantitative Assessment of Food Effect on the Pharmacokinetics of Nano-Crystallized Megestrol Acetate.
Chae, DW; Guk, J; Park, K; Son, H, 2017
)
0.93

Compound-Compound Interactions

Hysteroscopic resection combined with megestrol acetate has superior clinical efficacy. It can greatly increase the success rate of pregnancy and reduce the serum CA125 level.

ExcerptReferenceRelevance
" After addition and in combination with tamoxifen this LHRH-agonist treatment caused an objective response in about half (8/17) of the patients."( Long-term LHRH-agonist treatment in metastatic breast cancer as a single treatment and in combination with other additive endocrine treatments.
Klijn, JG, 1984
)
0.27
"This study aimed to evaluate the efficacy of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young patients with endometrial atypical hyperplasia (EAH) and early stage endometrial cancer (EEC) who wished to preserve their fertility."( Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Chen, X; Luo, X; Ning, C; Shan, W; Shi, Y; Xie, B; Xie, L; Xu, Y; Yang, B; Zhang, H; Zhu, Q, 2019
)
0.51
" All patients received constant oral progestin combined with hysteroscopic evaluation every 3 months until achieving complete response (CR)."( Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
Chen, X; Luo, X; Ning, C; Shan, W; Shi, Y; Xie, B; Xie, L; Xu, Y; Yang, B; Zhang, H; Zhu, Q, 2019
)
0.51
"To explore the clinical efficacy of hysteroscopic resection combined with megestrol acetate in the treatment of patients with early-stage endometrial cancer (EC) and its prognosis."( Curative effects of hysteroscopic resection combined with progesterone on early-stage endometrial cancer and its prognosis.
Ke, F; Kuang, J; Ni, R; Sun, S; Xu, H,
)
0.36
"130 patients with early-stage EC were divided into two groups: MA group (hysteroscopic resection combined with megestrol acetate, n=65) and Control group (hysteroscopic resection alone, n=65)."( Curative effects of hysteroscopic resection combined with progesterone on early-stage endometrial cancer and its prognosis.
Ke, F; Kuang, J; Ni, R; Sun, S; Xu, H,
)
0.34
"Hysteroscopic resection combined with megestrol acetate has superior clinical efficacy to hysteroscopic resection alone in the treatment of patients with early-stage EC, which can greatly increase the success rate of pregnancy and reduce the serum CA125 level."( Curative effects of hysteroscopic resection combined with progesterone on early-stage endometrial cancer and its prognosis.
Ke, F; Kuang, J; Ni, R; Sun, S; Xu, H,
)
0.4

Bioavailability

Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food. Because the bioavailability of megestrol acetates directly affects its efficacy and safety, the formulation was refined to enhance its pharmacokinetics.

ExcerptReferenceRelevance
"This study is aimed at developing a rapid, simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to determine anisatin's bioavailability in mouse blood and the method's application to pharmacokinetics."( Bioavailability and Pharmacokinetics of Anisatin in Mouse Blood by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Bao, X; Jiang, X; Ma, J; Wang, X; Zhou, Q, 2020
)
0.56
"5 mg/kg) administration of anisatin to mice-the absolute bioavailability of anisatin in the mouse blood was 22."( Bioavailability and Pharmacokinetics of Anisatin in Mouse Blood by Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry.
Bao, X; Jiang, X; Ma, J; Wang, X; Zhou, Q, 2020
)
0.56
"Serum levels of cortisol (C), androstenedione (A), dehydroepiandrosterone (D), estrone (E1) and estradiol (E2) were chosen as parameters to compare the bioavailability of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in postmenopausal patients with advanced breast cancer."( Adrenal steroids as parameters of the bioavailability of MA and MPA.
Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990
)
0.47
"8 h), the absorption rate constant was the same for each of the tablets."( Evaluation of two new megestrol acetate tablet formulations in humans.
Breault, GO; Fenzl, E; Gaver, RC; Goodson, PJ; Pittman, KA; Reilly, CM,
)
0.45
"8 h) the rate of absorption was the same for each of the tablets."( Bioequivalence evaluation of new megestrol acetate formulations in humans.
Breault, GO; Fenzl, E; Gaver, RC; Goodson, PJ; Pittman, KA; Reilly, CM; Smyth, RD, 1985
)
0.55
" The trend to higher bioavailability of the new formulation was not significant, especially as compared with the dose-response data reported in the literature."( Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies.
Cacciari, N; Camaggi, CM; Martoni, A; Pannuti, F; Pavesi, L; Robustelli della Cuna, G; Silva, A; Strocchi, E; Tedeschi, M; Zamagni, C, 1995
)
0.53
" Bioavailability of the drug following oral administration is closely related to the effectiveness and safety profile of the drug in formulation."( Improved bioavailability of a micronized megestrol acetate tablet formulation in humans.
Bica, A; Farinha, A; Tavares, P, 2000
)
0.57
"Several Pluronic-based formulations were studied in-vitro and in a rat model with respect to the release and bioavailability of megestrol acetate (MA) after oral administration."( Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate.
Alakhov, V; Bromberg, L; Hatton, TA; Kabanov, A; Patel, K; Pietrzynski, G, 2004
)
0.75
" Because the bioavailability of megestrol acetate directly affects its efficacy and safety, the formulation was refined to enhance its pharmacokinetics."( The science of megestrol acetate delivery: potential to improve outcomes in cachexia.
Femia, RA; Goyette, RE, 2005
)
0.96
"Nanonization is a simple and effective method to improve dissolution rate and oral bioavailability of drugs with poor water solubility."( Nanonization of megestrol acetate by laser fragmentation in aqueous milieu.
Furtos, A; Leclair, G; Leroux, JC; Meunier, M; Sylvestre, JP; Tang, MC, 2011
)
0.72
"In order to enhance the dissolution profile and oral bioavailability of megestrol acetate (MA), solid dispersions of MA (MASDs) were formulated with copovidone and crystal sugar as a hydrophilic polymeric carrier and an inert core bead, respectively."( Solid dispersion formulations of megestrol acetate with copovidone for enhanced dissolution and oral bioavailability.
Choi, SU; Choi, YW; Hong, SW; Jeon, HR; Kang, MH; Lee, BS; Lee, J; Moon, KY; Park, SH; Park, SJ; Song, WH, 2011
)
0.88
" However, Megace oral suspension (OS), a micronized formulation of megestrol acetate, has low bioavailability in the fasting state."( Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state.
Cho, JY; Jang, IJ; Jang, K; Kim, SE; Lee, H; Lim, KS; Yoon, S; Yoon, SH; Yu, KS, 2014
)
0.92
" Then oral bioavailability of MGA NE and MGA MS was evaluated."( Nanomemulsion of megestrol acetate for improved oral bioavailability and reduced food effect.
Kim, MK; Lee, DH; Li, Y; Lim, H; Shen, Q; Song, CK; Yang, SG, 2015
)
0.76
" The dissolution and oral bioavailability of the nanoparticles were also evaluated in rats."( Development of megestrol acetate solid dispersion nanoparticles for enhanced oral delivery by using a supercritical antisolvent process.
Baek, IH; Ha, ES; Jung, Y; Kim, JS; Kim, MS; Moon, HR; Yoo, JW, 2015
)
0.77
" The conventional suspension of megestrol acetate contains micronized megestrol acetate, which was recently discovered to have a disadvantage of decreasing bioavailability when taken in a fasting state."( Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
Chae, DW; Guk, J; Park, C; Park, K; Son, H, 2016
)
0.97
" Our findings suggest that the test formulation of megestrol-acetate-containing nanocrystals is better absorbed and has higher bioavailability compared to the reference formulation in a fasting state."( Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
Chae, DW; Guk, J; Park, C; Park, K; Son, H, 2016
)
0.69
"Megestrol acetate, an appetite stimulant with low bioavailability, shows increased bioavailability when taken together with food."( Quantitative Assessment of Food Effect on the Pharmacokinetics of Nano-Crystallized Megestrol Acetate.
Chae, DW; Guk, J; Park, K; Son, H, 2017
)
2.12
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The oral absorption rate in rats increased with particle size reduction."( The elucidation of key factors for oral absorption enhancement of nanocrystal formulations: In vitro-in vivo correlation of nanocrystals.
Imono, M; Kadota, K; Miyazaki, S; Tamura, N; Tozuka, Y; Tsutsumimoto, H; Uchiyama, H; Yoshida, S, 2020
)
0.56
"Many active pharmaceutical ingredients (API) are poorly soluble in water and their low oral bioavailability is a major hindrance to their potential use."( Nanoemulsions Containing Megestrol Acetate: Development, Characterization, and Stability Evaluation.
Tirnaksiz, F; Tuncel, E; Yalcin, TE; Yucel, C, 2022
)
1.02

Dosage Studied

Megestrol acetate is a progestogen widely used in the palliative treatment of endometrial carcinoma and breast cancer. Dose-response studies have demonstrated increasing efficacy with increasing doses of megestrolacetate from 160 to 800 mg/day.

ExcerptRelevanceReference
" Anisatin shifted the dose-response curve for GABA-induced depolarization in the primary afferent terminal to the right and also reduced the maximum response to GABA."( Anisatin, a potent GABA antagonist, isolated from Illicium anisatum.
Kudo, Y; Oka, JI; Yamada, K, 1981
)
0.26
" Dose-response studies have demonstrated increasing efficacy with increasing doses of megestrol acetate from 160 to 800 mg/day."( Nutrition in advanced cancer: anorexia as an outcome variable and target of therapy.
Ashley, J; Halpert, C; Heber, D; Tchekmedyian, NS,
)
0.35
" It is hoped that these results will provide a definitive answer to the dose-response issue for breast cancer."( Potential applications of high-dose megestrol acetate in breast cancer.
Abrams, JS; Aisner, J; Gutheil, J, 1992
)
0.56
" No correlation between megestrol acetate dosage and weight gain was found, but there was a tendency for increased weight in more patients taking high-dose megestrol acetate."( Risks and benefits of various therapies for cancer anorexia.
Schmoll, E, 1992
)
0.59
" Ongoing clinical trials are evaluating the dose-response relationship of megestrol acetate for these clinical problems and whether megestrol acetate will improve the survival of patients at risk for developing cancer anorexia/cachexia."( Megestrol acetate for anorexia and cachexia.
Jensen, M; Johnson, PA; Loprinzi, CL, 1992
)
1.96
" Doubling the dose of either drug did not enhance hormone suppression, indicating that the drug dosage is maximally suppressive."( Adrenal steroids as parameters of the bioavailability of MA and MPA.
Dikkeschei, LD; Sleijfer, DT; Tjabbes, T; van Veelen, H; Willemse, PH, 1990
)
0.28
" Many investigators have reported that progestogen with high dosage shows a good response to advanced endometrial cancer."( [Therapy of advanced endometrial cancer].
Okada, H; Yamamoto, T, 1990
)
0.28
" Attempts to further enhance the role of progestins have centered on dosage escalation, based on European data suggesting a dose-response effect."( Current status of high-dose progestins in breast cancer.
Abrams, JS; Aisner, J; Parnes, H, 1990
)
0.28
" There is apparently a dose-response between megestrol acetate and breast cancer, along with a response dependent on the number and type of estrogen and progestin receptors."( Megestrol acetate: clinical experience.
Canetta, R; Kelley, S; Nicaise, C; Rozencweig, M; Schacter, L; Smaldone, L, 1989
)
1.98
" Effects on cortisol persisted for two weeks after MA dosage ceased."( Comparative effects of proligestone and megestrol acetate on basal plasma glucose concentrations and cortisol responses to exogenous adrenocorticotrophic hormone in cats.
Church, DB; Emslie, DR; Middleton, DJ; Watson, AD, 1989
)
0.54
" This is a follow-up report on the 434 women who used this 'optional' dosage of compound by before-and-after comparisons and by comparisons with two other groups of women: 41 women who were given the compound with the same dosage combination but with microencapsular coat dissolved, and 20-30 women who were using a non-steroidal contraceptive method such as IUDs, barrier or rhythm methods."( A follow-up study of the efficacy and safety of injectable microencapsulated megestrol acetate and a discussion on its contraceptive mechanism.
Han, ZY; Xiao, RQ, 1985
)
0.5
" Although the dose-dependent mode of actions of MPA have been extensively clarified, there is still some uncertainty regarding the mode of actions and dosage of MA."( [Megestrol acetate in various doses in the treatment of metastatic breast carcinoma--clinical and endocrinologic studies].
Blossey, HC; Emrich, D; Nagel, GA; Wander, HE, 1985
)
1.18
" Plasma levels of megestrol acetate averaged 600 ng/mL in the first month of therapy and decreased to approximately 400 ng/mL at 8 and 12 weeks, after the drug dosage had been reduced."( High-dose megestrol acetate therapy of ovarian carcinoma: a phase II study by the Northern California Oncology Group.
Ballon, SC; Brandt, AE; Christman, JE; Ehsan, MN; Evans, TL; Scudder, SA; Sikic, BI; Soriero, OM; Suey, L, 1986
)
1.01
"A dose-response relationship has long been suspected for progestin compounds in the treatment of breast cancer, but only recently have trials been implemented to investigate this issue."( High-dose megestrol acetate in the treatment of advanced breast cancer.
Abrams, J; Aisner, J; Tait, N; Tchekmedyian, NS, 1988
)
0.68
" Sequential studies suggest a steep dose-response relationship for medroxyprogesterone."( High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities.
Aisner, J; Moody, M; Tait, N; Tchekmedyian, NS, 1987
)
0.68
"The optimal dose of progesterone compounds for the treatment of breast cancer is unknown, but there is evidence to suggest a dose-response curve."( High-dose megestrol acetate in the treatment of postmenopausal women with advanced breast cancer.
Aisner, J; Tait, N; Tchekmedyian, NS, 1986
)
0.67
"A comparative clinical study was undertaken by the Sichuan Cooperative Research Group for Microencapsulated Contraceptives to assess the efficacy of intramuscular microencapsulated megestrol compound as a long-acting contraceptive and to find the optimal dosage as regards efficacy, side effects and menstrual irregularities."( Clinical evaluation of intramuscular injection of microencapsulated compound megestrol acetate.
Han, ZY; Xiao, RQ, 1984
)
0.5
" The dosage schedule was 5 mg orally per day per cat for seven days, then 5 mg every three days for 21 days."( The use of megestrol acetate in some feline dermatological problems.
Chalifoux, A; Gosselin, Y; Papageorges, M, 1981
)
0.65
" Further differentiation of 400 vs 800 mg arms was seen in the BACRI-7 results, consistent with dose-response improvements in weight and lean body mass changes."( The Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI): a brief assessment of patients' subjective response to treatment for anorexia/cachexia.
Browder, HP; Cella, DF; Lloyd, S; VonRoenn, J, 1995
)
0.29
" The trend to higher bioavailability of the new formulation was not significant, especially as compared with the dose-response data reported in the literature."( Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies.
Cacciari, N; Camaggi, CM; Martoni, A; Pannuti, F; Pavesi, L; Robustelli della Cuna, G; Silva, A; Strocchi, E; Tedeschi, M; Zamagni, C, 1995
)
0.53
" Toxicity was tolerable, and more than 80% of ideal dosing was achieved during the first two cycles of treatment."( Megestrol melanoma study.
Garrison, M; Nathanson, L,
)
0.13
" There may be a trend toward a dose-response effect, which represents a suitable topic for a future prospective trial."( Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
Ahlgren, JD; Alt, D; Ellison, NM; Gottlieb, RJ; Laluna, F; Lokich, JJ; Sinclair, PR; Ueno, W; Wampler, GL; Yeung, KY, 1993
)
0.29
" A statistically significant correlation between the ratio of body weight at 3 weeks/initial weight (weight index) and the percentage of the 24-h dosing interval that megestrol acetate concentrations exceeded a 300-ng/ml threshold was observed."( Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients.
Dudley, MN; Fisher, AE; Graham, KK; Mikolich, DJ; Posner, MR, 1994
)
0.78
" The cats given MA (n = 7) developed significant suppression of plasma ACTH concentrations and hyperinsulinaemia during treatment and for two to four weeks after MA dosage ceased."( Effects of proligestone and megestrol on plasma adrenocorticotrophic hormone, insulin and insulin-like growth factor-1 concentrations in cats.
Church, DB; Emslie, DR; Middleton, DJ; Tan, K; Watson, AD; Wong, D, 1994
)
0.29
"The impact of the side effects of megestrol acetate on the quality of life of noncachectic women with advanced breast cancer was studied in a dose-response clinical trial of the Cancer and Leukemia Group B (CALGB 8741)."( Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B.
Abrams, J; Aisner, J; Canellos, GP; Cooper, MR; Herndon, JE; Hollis, DR; Kornblith, AB; Lyss, AP; Phillips, CA; Zuckerman, E, 1993
)
0.97
"The data demonstrate that there is a positive dose-response effect for megestrol acetate on appetite stimulation (P < or = ."( Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
Athmann, LM; Goldberg, RM; Hatfield, AK; Loprinzi, CL; Mailliard, JA; Michalak, JC; Morton, RF; Schaid, DJ; Tschetter, LK, 1993
)
0.79
"The positive dose-response effect that we observed for megestrol acetate on appetite stimulation supports both our prestudy hypothesis and other available literature."( Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia.
Athmann, LM; Goldberg, RM; Hatfield, AK; Loprinzi, CL; Mailliard, JA; Michalak, JC; Morton, RF; Schaid, DJ; Tschetter, LK, 1993
)
0.8
" dosing with 100 mg/kg CPA once a week for 6 successive weeks induced, as compared to controls, a significant increase in the number and area of gamma-glutamyltranspeptidase-positive foci."( Induction of micronuclei and initiation of enzyme-altered foci in the liver of female rats treated with cyproterone acetate, chlormadinone acetate, or megestrol acetate.
Allavena, A; Brambilla Campart, G; Brambilla, G; Ghia, M; Martelli, A; Mereto, E, 1996
)
0.49
" Moreover, data concerning the dose escalation of MA dosage in unresponsive patients suggest that a step by step increase in MA dosage could be the best way of administering MA for the management of ACS and that the increase of MA dosage over 480 mg day-1 will probably be useless in the vast majority of cases."( Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer.
Gebbia, N; Gebbia, V; Testa, A, 1996
)
0.55
" Megestrol acetate, in the dosage range of 400 to 800 mg/day, is a useful appetite stimulant for the prevention and treatment of HIV-associated wasting, particularly in women."( Megestrol acetate: promises and pitfalls.
Farrar, DJ, 1999
)
2.66
" Based on limited data suggesting a possible dose-response effect, a trial was initiated to compare standard versus moderately high dose MA in HRPC."( A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
Conaway, M; Dawson, NA; Halabi, S; Lake, D; Small, EJ; Vogelzang, NJ; Winer, EP, 2000
)
0.54
"MA has limited activity in hormone-refractory prostate carcinoma, and there is no apparent dose-response correlation."( A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma: cancer and leukemia group B study 9181.
Conaway, M; Dawson, NA; Halabi, S; Lake, D; Small, EJ; Vogelzang, NJ; Winer, EP, 2000
)
0.54
"Megestrol acetate, a progestogen widely used in the palliative treatment of endometrial carcinoma and breast cancer, is currently administered orally as a solid dosage form."( Improved bioavailability of a micronized megestrol acetate tablet formulation in humans.
Bica, A; Farinha, A; Tavares, P, 2000
)
2.02
" Preclinical research has demonstrated that the estrogen dose-response curve for breast cancer cells can be shifted by modification of the estrogen environment."( Estrogen as therapy for breast cancer.
Ingle, JN, 2002
)
0.31
" An antithromboembolic effects was suggested with an increasing combined dosage of norethisterone acetate."( Thromboembolic disease and the steroidal content of oral contraceptives.
Swyer, GI, 1970
)
0.25
" Dosage used should be minimum, compatible with efficacy for both the estrogens and the progestogens."( Metabolic effects of contraceptive steroids IV. Liver function tests--short term observations.
Chaudhury, RR; Devi, PK; Gupta, I; Nath, R, 1972
)
0.25
"In order to study the appropriate dosage in using RU 486 for induced abortion, 80 women of or = 49 days of pregnancy were randomly assigned to 3 groups."( [Clinical study of termination of early pregnancy by combination of dl-15-methyl-prostaglandin F2 alpha and RU 486].
Jin, YC; Li, H; Song, JY; Wan, GG; Xu, MF; Zhong, HP; Zhou, YF, 1993
)
0.29
" Microgels of Pluronic L92 and poly(acrylic acid) fabricated into tablet dosage forms exhibited dramatically lowered MA initial burst release."( Pluronic block copolymers and Pluronic poly(acrylic acid) microgels in oral delivery of megestrol acetate.
Alakhov, V; Bromberg, L; Hatton, TA; Kabanov, A; Patel, K; Pietrzynski, G, 2004
)
0.55
"To provide preliminary evidence on the effectiveness and optimal dosage of megestrol acetate for older persons with impaired appetite after hospitalization."( The effects of megestrol acetate suspension for elderly patients with reduced appetite after hospitalization: a phase II randomized clinical trial.
Greendale, GA; Hirsch, SH; Reuben, DB; Zhou, K, 2005
)
0.91
" Par Pharmaceutical used Elan Corporation's NanoCrystal Dispersion (NCD) technology to develop an advanced, concentrated formulation of megestrol acetate with improved bioavailability, more rapid onset of action, more convenient dosing and a lower dosing regimen compared with the original marketed formulation of megestrol acetate oral suspension."( Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.
, 2007
)
1.99
" Par Pharmaceutical used Elan Corporation's NanoCrystal Dispersion (NCD) technology to develop an advanced, concentrated formulation of megestrol acetate with improved bioavailability, more rapid onset of action, more convenient dosing and a lower dosing regimen compared with the original marketed formulation of megestrol acetate oral suspension."( Megestrol acetate NCD oral suspension--Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.
, 2007
)
1.99
" It has been also proposed that negative results might be explained if tamoxifen acts in HCC via an estrogen receptor-independent pathway, that requires higher doses than those usually administered, but an Asian RCT conducted to assess dose-response effect was completely negative."( Is human hepatocellular carcinoma a hormone-responsive tumor?
Daniele, B; De Maio, E; Di Maio, M; Gallo, C; Morabito, A; Perrone, F; Piccirillo, MC; Pignata, S, 2008
)
0.35
" In patients who did not respond to treatment, the dosage of the drug was doubled (320 mg/d), and the therapy continued for another 3 months."( Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients.
Eftekhar, Z; Izadi-Mood, N; Mohagheghi, S; Rezaei, Z; Shojaei, H; Yarandi, F, 2009
)
0.73
"78%) with a dosage of 160 mg/d, and the remaining patients with 320 mg/d."( Efficacy of megestrol acetate (megace) in the treatment of patients with early endometrial adenocarcinoma: our experiences with 21 patients.
Eftekhar, Z; Izadi-Mood, N; Mohagheghi, S; Rezaei, Z; Shojaei, H; Yarandi, F, 2009
)
0.73
" We conclude that MASD (1:1) is a good candidate for the development of oral solid dosage forms."( Solid dispersion formulations of megestrol acetate with copovidone for enhanced dissolution and oral bioavailability.
Choi, SU; Choi, YW; Hong, SW; Jeon, HR; Kang, MH; Lee, BS; Lee, J; Moon, KY; Park, SH; Park, SJ; Song, WH, 2011
)
0.65
"Megestrol acetate (MGA) belongs to the BCS class II drugs with low solubility and high permeability, and its oral absorption in conventional dosage form MGA microcrystal suspension (MGA MS) is very limited and greatly affected by food."( Nanomemulsion of megestrol acetate for improved oral bioavailability and reduced food effect.
Kim, MK; Lee, DH; Li, Y; Lim, H; Shen, Q; Song, CK; Yang, SG, 2015
)
2.2
"Hysteroscopic resection of hyperplastic and/or cancer areas before high dosage progestin therapy seems to be a safe and effective approach in the management of ACH and in patients with early EC who wish to preserve fertility."( Hysteroscopic Resection in Fertility-Sparing Surgery for Atypical Hyperplasia and Endometrial Cancer: Safety and Efficacy.
Bergamini, A; Candiani, M; Colombo, G; De Marzi, P; Luchini, S; Mangili, G; Petrone, M; Taccagni, GL,
)
0.13
" The dosage of morphine was counted as defined daily dose and its effect was assessed by multivariable Cox proportional hazard regression controlling age, Charlson comorbidity index, outpatient department visits, antipsychotics, and breast cancer drugs."( Risk of type 2 diabetes mellitus in female breast cancer patients treated with morphine: A retrospective population-based time-dependent cohort study.
Chang, YJ; Lai, SW; Lee, CW; Morisky, DE; Muo, CH; Wang, IK; Yang, SP, 2015
)
0.42
" Blood sampling was performed up to 120 hours after dosing using a pre-specified sampling time scheme."( Pharmacokinetics of a nanocrystal-containing megestrol acetate formulation: a single-dose, randomized, open-label, 2-part, 2-period crossover study in healthy Korean subjects.
Chae, DW; Guk, J; Park, C; Park, K; Son, H, 2016
)
0.69
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (9)

RoleDescription
GABA antagonistA compound that inhibits the action of gamma-aminobutyric acid.
neurotoxinA poison that interferes with the functions of the nervous system.
phytogenic insecticideAn insecticide compound naturally occurring in plants.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
appetite enhancerA drug which increases appetite.
contraceptive drugA chemical substance that prevents or reduces the probability of conception.
progestinA synthetic progestogen.
synthetic oral contraceptiveAn oral contraceptive which owes its effectiveness to synthetic preparation.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (11)

ClassDescription
tetrolA polyol that contains 4 hydroxy groups.
sesquiterpene lactoneAny member of a diverse class of complex, multicyclic phytochemicals showing a variety of skeleton arrangements and bioactivities, and having in common a sesquiterpenoid structure including a lactone ring.
spiro compoundA compound having one atom as the only common member of two rings.
organic heterotetracyclic compound
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
secondary alcoholA secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it.
bridged compoundA polycyclic compound in which two rings have two or more atoms in common.
steroid ester
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
3-oxo-Delta(4) steroidA 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (55)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Beta-lactamaseEscherichia coli K-12Potency19.95260.044717.8581100.0000AID485341
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
RAR-related orphan receptor gammaMus musculus (house mouse)Potency22.14250.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency16.94070.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency16.94070.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency26.10110.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency11.87020.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency2.64620.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency7.94330.00137.762544.6684AID914; AID915
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency66.67120.001022.650876.6163AID1224838; AID1224893
progesterone receptorHomo sapiens (human)Potency13.71990.000417.946075.1148AID1346784; AID1346795; AID1347036
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency8.70900.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency0.07030.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency19.89630.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency18.43080.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency23.54620.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency61.64480.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency22.04570.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency26.85600.000229.305416,493.5996AID743069; AID743075; AID743078
GVesicular stomatitis virusPotency12.30180.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency18.00400.001024.504861.6448AID743212
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency13.80060.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency12.50710.023723.228263.5986AID743222
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency39.81070.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.10530.001723.839378.1014AID743083
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency10.182419.739145.978464.9432AID1159509
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency8.91250.10009.191631.6228AID1346983
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.73080.00419.984825.9290AID504444
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency20.29250.000323.4451159.6830AID743065; AID743067
DNA polymerase betaHomo sapiens (human)Potency70.79460.022421.010289.1251AID485314
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency12.88070.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency0.58050.004611.374133.4983AID624297
survival motor neuron protein isoform dHomo sapiens (human)Potency1.25890.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
lamin isoform A-delta10Homo sapiens (human)Potency8.91250.891312.067628.1838AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency3.57170.015812.3113615.5000AID1461
Interferon betaHomo sapiens (human)Potency12.30180.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency45.62940.002319.595674.0614AID651631
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency38.57080.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency38.57080.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency12.30180.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)13.90000.11007.190310.0000AID1449628; AID1473738
Glucocorticoid receptorHomo sapiens (human)IC50 (µMol)0.01900.00000.495310.0000AID625263
Glucocorticoid receptorHomo sapiens (human)Ki0.00880.00010.38637.0010AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)0.01900.00150.76005.0740AID625263
Glycine receptor subunit alpha-1Rattus norvegicus (Norway rat)Ki0.00880.00070.76537.0010AID625263
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)10.00000.00002.800510.0000AID625248
Androgen receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03000.00101.979414.1600AID625228
Androgen receptorRattus norvegicus (Norway rat)Ki0.02000.00031.21858.9270AID625228
Glycine receptor subunit betaRattus norvegicus (Norway rat)IC50 (µMol)0.01900.00150.76005.0740AID625263
Glycine receptor subunit betaRattus norvegicus (Norway rat)Ki0.00880.00070.78467.0010AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)0.01900.00150.80445.0740AID625263
Glycine receptor subunit alpha-2Rattus norvegicus (Norway rat)Ki0.00880.00070.78467.0010AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)0.01900.00150.76005.0740AID625263
Glycine receptor subunit alpha-3Rattus norvegicus (Norway rat)Ki0.00880.00070.78467.0010AID625263
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
bioAMycobacterium tuberculosis UT205AC5011.01000.38907.681815.4100AID651683
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (263)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
regulation of gluconeogenesisGlucocorticoid receptorHomo sapiens (human)
chromatin organizationGlucocorticoid receptorHomo sapiens (human)
regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
apoptotic processGlucocorticoid receptorHomo sapiens (human)
chromosome segregationGlucocorticoid receptorHomo sapiens (human)
signal transductionGlucocorticoid receptorHomo sapiens (human)
glucocorticoid metabolic processGlucocorticoid receptorHomo sapiens (human)
gene expressionGlucocorticoid receptorHomo sapiens (human)
microglia differentiationGlucocorticoid receptorHomo sapiens (human)
adrenal gland developmentGlucocorticoid receptorHomo sapiens (human)
regulation of glucocorticoid biosynthetic processGlucocorticoid receptorHomo sapiens (human)
synaptic transmission, glutamatergicGlucocorticoid receptorHomo sapiens (human)
maternal behaviorGlucocorticoid receptorHomo sapiens (human)
intracellular glucocorticoid receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
glucocorticoid mediated signaling pathwayGlucocorticoid receptorHomo sapiens (human)
positive regulation of neuron apoptotic processGlucocorticoid receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionGlucocorticoid receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
astrocyte differentiationGlucocorticoid receptorHomo sapiens (human)
cell divisionGlucocorticoid receptorHomo sapiens (human)
mammary gland duct morphogenesisGlucocorticoid receptorHomo sapiens (human)
motor behaviorGlucocorticoid receptorHomo sapiens (human)
cellular response to steroid hormone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to glucocorticoid stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to dexamethasone stimulusGlucocorticoid receptorHomo sapiens (human)
cellular response to transforming growth factor beta stimulusGlucocorticoid receptorHomo sapiens (human)
neuroinflammatory responseGlucocorticoid receptorHomo sapiens (human)
positive regulation of miRNA transcriptionGlucocorticoid receptorHomo sapiens (human)
intracellular steroid hormone receptor signaling pathwayGlucocorticoid receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIGlucocorticoid receptorHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (100)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
core promoter sequence-specific DNA bindingGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificGlucocorticoid receptorHomo sapiens (human)
DNA-binding transcription factor activityGlucocorticoid receptorHomo sapiens (human)
RNA bindingGlucocorticoid receptorHomo sapiens (human)
nuclear receptor activityGlucocorticoid receptorHomo sapiens (human)
nuclear glucocorticoid receptor activityGlucocorticoid receptorHomo sapiens (human)
steroid bindingGlucocorticoid receptorHomo sapiens (human)
protein bindingGlucocorticoid receptorHomo sapiens (human)
zinc ion bindingGlucocorticoid receptorHomo sapiens (human)
TBP-class protein bindingGlucocorticoid receptorHomo sapiens (human)
protein kinase bindingGlucocorticoid receptorHomo sapiens (human)
identical protein bindingGlucocorticoid receptorHomo sapiens (human)
Hsp90 protein bindingGlucocorticoid receptorHomo sapiens (human)
steroid hormone bindingGlucocorticoid receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingGlucocorticoid receptorHomo sapiens (human)
estrogen response element bindingGlucocorticoid receptorHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (55)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleusGlucocorticoid receptorHomo sapiens (human)
nucleoplasmGlucocorticoid receptorHomo sapiens (human)
cytoplasmGlucocorticoid receptorHomo sapiens (human)
mitochondrial matrixGlucocorticoid receptorHomo sapiens (human)
centrosomeGlucocorticoid receptorHomo sapiens (human)
spindleGlucocorticoid receptorHomo sapiens (human)
cytosolGlucocorticoid receptorHomo sapiens (human)
membraneGlucocorticoid receptorHomo sapiens (human)
nuclear speckGlucocorticoid receptorHomo sapiens (human)
synapseGlucocorticoid receptorHomo sapiens (human)
chromatinGlucocorticoid receptorHomo sapiens (human)
protein-containing complexGlucocorticoid receptorHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGlycine receptor subunit betaRattus norvegicus (Norway rat)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (138)

Assay IDTitleYearJournalArticle
AID277075Inhibition of human MMP9 by quenched fluorescense assay2006Bioorganic & medicinal chemistry letters, Dec-15, Volume: 16, Issue:24
Natural inhibitors targeting osteoclast-mediated bone resorption.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1474012Drug concentration at steady state in human at 400 to 800 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1150121Relative binding affinity to human progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1474013Ratio of drug concentration at steady state in human at 400 to 800 mg, po QD after 24 hrs to IC50 for human BSEP overexpressed in Sf9 insect cells2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID409959Inhibition of bovine liver MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID679730TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 2 mg/mL, Megestrol acetate: 25 uM) in MCF-7/ADR cells, flow cytometry1994Cancer chemotherapy and pharmacology, , Volume: 34, Issue:2
Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID679729TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 2 mg/mL, Megestrol acetate: 50 uM) in HCT-116/VM46 cells, flow cytometry1994Cancer chemotherapy and pharmacology, , Volume: 34, Issue:2
Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1474011AUC in human at 400 to 800 mg, po QD after 24 hrs2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1150122Relative binding affinity to sheep progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID1150124Relative binding affinity to guinea pig progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID409957Inhibition of bovine liver MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1150123Relative binding affinity to rabbit progesterone receptor1977Journal of medicinal chemistry, Sep, Volume: 20, Issue:9
Quantitative relationships between steroid structure and binding to putative progesterone receptors.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (903)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990175 (19.38)18.7374
1990's282 (31.23)18.2507
2000's238 (26.36)29.6817
2010's167 (18.49)24.3611
2020's41 (4.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 85.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index85.92 (24.57)
Research Supply Index7.06 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index157.49 (26.88)
Search Engine Supply Index2.02 (0.95)

This Compound (85.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials228 (24.44%)5.53%
Reviews2 (7.14%)6.00%
Reviews119 (12.75%)6.00%
Case Studies2 (7.14%)4.05%
Case Studies107 (11.47%)4.05%
Observational0 (0.00%)0.25%
Observational5 (0.54%)0.25%
Other24 (85.71%)84.16%
Other474 (50.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (72)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of DW-ES(B) and Megace® Under Fed Conditions in Healthy Male Volunteers [NCT01589562]Phase 128 participants (Anticipated)Interventional2012-04-30Completed
A Phase 2, Single Arm, Two Period Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Endometrial Carcinoma [NCT03077698]Phase 225 participants (Actual)Interventional2017-06-14Terminated(stopped due to The study was discontinued due to a change in development strategy and not due safety concern.)
Prospective Clinical Study of the Effect of Thalidomide Combined With Megestrol Acetate on Lymphocyte, Inflammatory Factor Regulation and Nutritional Status in Patients With Advanced Malignant Tumors [NCT03777930]Phase 4200 participants (Anticipated)Interventional2018-12-10Not yet recruiting
Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia [NCT03241888]Phase 2/Phase 3180 participants (Actual)Interventional2017-07-04Completed
Phase 1 Study of Daewon-ES(A) & Daewon-ES(B) in Healthy Male Volunteers Under Fed Condition [NCT01383330]Phase 115 participants (Anticipated)Interventional2011-07-31Not yet recruiting
Evidence-based Medical Research on the Treatment of Children's Rapid Progressive Central Precocious Puberty With Integrative Chinese and Western Medicine [NCT03963752]Phase 4164 participants (Anticipated)Interventional2019-08-15Recruiting
Levonorgestrel-Releasing Intrauterine System (LNG-IUS) in the Management of Atypical Endometrial Hyperplasia: A Non-Inferiority Study [NCT04897217]Phase 30 participants (Actual)Interventional2023-06-30Withdrawn(stopped due to PI decision)
Randomized, Double-blind Clinical Trial of the Use of Mirtazapine Versus Megestrol for the Control of Anorexia-cachexia in Cancer Patients in Palliative Care. [NCT03283488]Phase 252 participants (Actual)Interventional2019-03-26Completed
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia [NCT04491682]Phase 2/Phase 336 participants (Actual)Interventional2020-09-01Completed
Phase II Trial of Progressive Resistance Training With Megestrol Acetate for the Treatment of Cancer-Related Weight Loss [NCT00004912]Phase 20 participants Interventional2000-01-31Completed
Randomised Phase II Clinical Trial PIONEER- A Pre-operative wIndOw Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole aloNE in Post-menopausal Patients With ER-positive Breast Cancer [NCT03306472]Phase 2189 participants (Anticipated)Interventional2017-07-20Recruiting
A Randomized Phase II Trial of Temsirolimus (NCI-Supplied Agent, NSC # 683864) or the Combination of Hormonal Therapy Plus Temsirolimus in Women With Advanced, Persistent, or Recurrent Endometrial Carcinoma [NCT00729586]Phase 273 participants (Actual)Interventional2008-09-30Completed
A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of Apetrol ES and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers [NCT02446353]Phase 179 participants (Actual)Interventional2010-04-30Completed
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia. [NCT04576104]Phase 250 participants (Anticipated)Interventional2021-09-17Recruiting
A Phase IB and Randomized Phase II Trial of Megestrol Acetate With or Without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer [NCT05538897]Phase 1/Phase 296 participants (Anticipated)Interventional2023-03-31Suspended(stopped due to Other - Review of safety data of Phase IB)
Prospective Trial of Conservative Management of Atypical Endometrial Hyperplasia and Well to Moderately Differentiated Endometrial Carcinoma Using Megestrol Acetate [NCT00483327]Phase 231 participants (Actual)Interventional2007-06-30Completed
Gonadotropin-releasing Hormone Agonist Combined With Letrozole Compared With Megestrol Acetate or Medroxyprogesterone Acetate Alone as Fertility-sparing Treatment in Early Endometrial Cancer [NCT05247268]Phase 2104 participants (Anticipated)Interventional2022-03-11Recruiting
A Phase II International Multicentre Randomised Open Label Study of Oral Steroid Sulphatase Inhibitor BN83495 Versus Megestrol Acetate (MA) in Women With Advanced or Recurrent Endometrial Cancer [NCT00910091]Phase 273 participants (Actual)Interventional2009-08-31Completed
Weight Management Plus Levonorgestrel Intrauterine System or Megestrol Acetate in Endometrial Atypical Hyperplasia: Multiple Single-arm, Prospective and Open-label Clinical Study [NCT05316493]Phase 2/Phase 3172 participants (Anticipated)Interventional2022-06-13Recruiting
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma: Two Single-arm, Prospective and Open-label Clinical Study [NCT05316467]Phase 2/Phase 389 participants (Anticipated)Interventional2022-05-01Recruiting
The Traditional Chinese Medicine Department of Xin Qiao Hospital [NCT02619266]Phase 2/Phase 3160 participants (Anticipated)Interventional2015-12-31Recruiting
A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients With Advanced Endometrial Carcinoma [NCT00739830]Phase 2130 participants (Actual)Interventional2008-08-31Completed
An Open-Label, Single-Dose Study to Assess the Effect of Renal Impairment on the Pharmacokinetic Characteristics, Safety, and Tolerability of Megestrol Acetate [NCT00637403]Phase 17 participants (Actual)Interventional2006-05-31Terminated(stopped due to Difficulty finding the required subject population)
Mirtazapine Versus Megestrol Acetate in Treatment of Anorexia-cachexia in Advanced Cancer Patients: A Randomized, Double-Blind Trail. [NCT05380479]Phase 280 participants (Anticipated)Interventional2022-06-01Recruiting
A Randomized, Open-label, Single-dose, Cross-over Study to Investigate Safety and Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers [NCT01397214]Phase 1103 participants (Actual)Interventional2011-07-31Completed
A Phase III, Double-Blind, Randomized Study Of The Effect Of Megestrol Acetate On Weight And Health Related Quality Of Life In Head And Neck Cancer Patients Receiving Radiation Therapy [NCT00006799]Phase 313 participants (Actual)Interventional2000-10-01Completed
A Phase III Trial of Placebo Versus Megestrol Acetate 20 MG/Day Versus Megestrol Acetate 40 MG/Day as Treatment for Symptoms of Ovarian Failure in Women Treated for Breast Cancer: SWOG Study S9626 [NCT00005975]Phase 3288 participants (Actual)Interventional1998-04-30Completed
A Phase II Head-to-Head Comparison of Fertility-Sparing Approaches to Treat Complex Atypical Hyperplasia of the Edometrium: Megestrol Versus Levonorgestrel-Releasing Intrauterine System (LNG-IUS) [NCT01943058]Phase 20 participants (Actual)Interventional2014-03-31Withdrawn(stopped due to Lack of funding)
Megestrol Acetate Plus Rosuvastatin in Young Women With Early Endometrial Carcinoma [NCT04491643]Phase 248 participants (Anticipated)Interventional2020-09-01Recruiting
A Randomized Phase II Evaluation of Continuous Progestin Therapy vs. Sequential Progestin Therapy in the Treatment of Endometrial Intraepithelial Neoplasia (EIN) From a Referred Cohort of Atypical Endometrial Hyperplasia (AEH) or EIN Patients That Desire [NCT00503581]Phase 29 participants (Actual)Interventional2007-07-31Terminated
Single-center, Randomized, Open-label, 2-way Crossover Bioavailability Study, Evaluating the Effect of Food on Megace ES (Megestrol Acetate 625 mg/5 mL Oral Suspension) Following a 625 mg Dose in Healthy Subjects [NCT00638079]Phase 124 participants (Actual)Interventional2006-06-30Completed
The Effect of Megestrol Acetate on Grade 2 Endometrioid Endometrial Cancer in Patients Waiting for Definitive Surgery, a Prospective Trial [NCT05332483]Phase 15 participants (Actual)Interventional2022-07-05Terminated(stopped due to Slow enrollment)
iKanEat: A Randomized-controlled, Multi-center Trial of Megestrol for Chronic Oral Food Refusal in Children 9 Months to 9 Years 0 Months of Age [NCT03815019]Phase 460 participants (Anticipated)Interventional2019-08-15Recruiting
Follow-up of the Study 971-ONC-0028-080: Exemestane Versus Megestrol Acetate In Postmenopausal Patients With Metastatic Breast Cancer, Failing Anti-Estrogens: An Open-Label, Randomized, Parallel-Group, Phase III Comparative Study [NCT01237327]Phase 384 participants (Actual)Interventional2001-11-30Completed
Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women With Endometrial Atypical Hyperplasia: A Randomized Controlled Pilot Clinical Study [NCT04683237]Phase 2/Phase 30 participants (Actual)Interventional2021-03-20Withdrawn(stopped due to Based on our latest research results, we will revise the protocol and design a better study. Since no participants are enrolled till now, we withdraw this study.)
Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia [NCT04607252]Phase 2/Phase 312 participants (Actual)Interventional2021-01-11Terminated(stopped due to Our clinical trial NCT03241888 showed LNG-IUS had a better treatment efficacy than Megestrol Acetate (MA) alone. The median CR time for MA group, LNG-IUS group and MA plus LNG-IUS group was 7.0±0.3 months, 4.4±1.0 months and 5.7±1.2 months.)
Megestrol Acetate For Failure To Thrive In Pediatric HIV [NCT00002182]25 participants InterventionalCompleted
The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia [NCT00066248]Phase 270 participants (Actual)Interventional2003-06-30Completed
A Phase III Randomized Study Comparing The Effects Of Oxandrolone (Oxandrin) And Megestrol Acetate (Megace) On Lean Body Mass, Weight, Body Fat, And Quality Of Life In Patients With Solid Tumors And Weight Loss Receiving Chemotherapy [NCT00070148]Phase 3155 participants (Actual)Interventional2004-03-01Completed
Randomized Trial,Comparative With Placebo, Double Blind, to Evaluate the Effect of the Treatment With 320 mg/d of Megestrol Acetate in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) and Loss of Body Weight. Pilot Study [NCT00507949]Phase 240 participants (Anticipated)Interventional2006-10-31Completed
Multicenter, Double Blind, Randomized, Clinical Trial, Controlled With Placebo, to Evaluate the Effect of the Treatment With 320 mg/Day of Megestrol Acetate During 24 Weeks in the Weight Loss in Mixed Dementia Patients. [NCT00503516]Phase 2/Phase 339 participants (Actual)Interventional2007-06-30Terminated(stopped due to Difficulties to recruit the patients following the inclusion criteria)
Phase I/II Study of High-Dose Megestrol in Breast or Endometrial Carcinoma or Mesothelioma [NCT00002465]Phase 1/Phase 20 participants Interventional1987-12-31Active, not recruiting
Randomized Phase III Crossover Trial of Chemotherapy (Doxorubicin/Cisplatin/Paclitaxel and G-CSF) Versus Hormonal Therapy (Tamoxifen/Megestrol Acetate) in Patients With Stage III & IV or Recurrent Endometrial Cancer [NCT00016341]Phase 30 participants Interventional2001-05-31Terminated
Randomized Double Blind Trial Of Megestrol Acetate Versus Placebo For The Treatment Of Inoperable Hepatocellular Carcinoma [NCT00041275]Phase 3300 participants (Anticipated)Interventional2002-05-31Completed
Phase III Double-Blind, Placebo-Controlled Randomized Comparison of Megestrol Acetate (Megace) Versus an N-3 Fatty Acid (EPA) Enriched Nutritional Supplement Versus Both for the Treatment of Cancer Cachexia and Anorexia [NCT00031707]Phase 3429 participants (Actual)Interventional2000-03-31Completed
A Phase III, Double-Blind, Randomized Study of the Effect of Megestrol Acetate on Weight and Health Related Quality of Life in Lung Cancer Patients Receiving Thoracic Radiation Therapy [NCT00031785]Phase 325 participants (Actual)Interventional2000-09-01Completed
Open-Label Randomized Phase II Trial of Megestrol Acetate With or Without Pterostilbene in Patients With Endometrial Cancer Scheduled for Hysterectomy [NCT03671811]Phase 244 participants (Actual)Interventional2019-01-21Active, not recruiting
Pharmacokinetics and Safety of Transdermal Megestrol Acetate [NCT00163072]Phase 40 participants (Actual)Interventional2005-10-31Withdrawn
Evaluation of the Time Course of Adrenal Suppression and Adrenal Recovery After Ingestion of Megestrol Acetate [NCT00575029]7 participants (Actual)Interventional2004-04-30Completed
A Phase II Study Assessing the Efficacy of Prophylaxis Use of Megestrol Acetate Against Cancer-related Critical Body Weight Loss in Patients With Head and Neck Cancer Who Receiving Concurrent Chemoradiotherapy [NCT02980653]Phase 2105 participants (Anticipated)Interventional2015-05-31Recruiting
Treatment of Cancer Anorexia-cachexia Syndrome (CACS) With Mirtazapine and Megestrol Acetate [NCT01501396]Phase 20 participants (Actual)Interventional2013-09-30Withdrawn
Megestrol Acetate Plus Metformin to Megestrol Acetate in Patients With Endometrial Atypical Hyperplasia or Early Stage Endometrial Adenocarcinoma [NCT01968317]Phase 2150 participants (Actual)Interventional2013-10-31Completed
Phase III Randomized Double-Blind Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia [NCT00002067]Phase 30 participants InterventionalCompleted
Phase II Trial of Sequential High-Dose Alkylating Agents in Metastatic Breast Cancer [NCT00002680]Phase 240 participants (Actual)Interventional1994-02-28Completed
A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Cancer of Multiple Types [NCT00637806]Phase 34 participants (Actual)Interventional2006-06-30Terminated(stopped due to Difficulty finding the required patient population)
A Randomized, Double-blind, Placebo-controlled Study of Megestrol Acetate Concentrated Suspension for the Treatment of Cancer-associated Anorexia in Subjects With Lung or Pancreatic Cancer [NCT00637728]Phase 35 participants (Actual)Interventional2006-06-30Terminated(stopped due to Difficulty finding the required patient population)
A Randomized, Open-labeled, Pilot Study Comparing Weight Gain in Adults With AIDS-related Wasting Given Either Megestrol Acetate Oral Suspension Nanocrystal Dispersion (MA-NCD) or Megestrol Acetate Oral Suspension (Megace) [NCT00637572]Phase 263 participants (Actual)Interventional2004-12-31Completed
Phase II-III Randomized Double-Blind Study Comparing Megestrol Acetate at 100, 400, and 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia [NCT00002300]Phase 20 participants InterventionalCompleted
A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome [NCT00000737]Phase 156 participants InterventionalCompleted
Double-Blind Randomized Comparison Phase II Trial of Megestrol Acetate and Testosterone Enanthate in Combination Versus Megestrol Acetate Plus Testosterone Enanthate Placebo in Human Immunodeficiency Virus (HIV)-Associated Wasting. [NCT00001079]Phase 280 participants InterventionalCompleted
Phase IV Study on the Safety and Efficacy of Megace Oral Suspension in HIV-Positive Females [NCT00002345]Phase 440 participants InterventionalCompleted
A Randomized Megestrol Acetate/Placebo Controlled Trial in Pediatric Patients With Malignancies With Weight Loss/Anorexia [NCT01200602]Phase 21 participants (Actual)Interventional2011-03-31Terminated(stopped due to The study closed due to slow accrual.)
Comparison of the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: a Prospective, Randomized Controlled Phase II Clini [NCT04430361]Phase 2120 participants (Anticipated)Interventional2018-09-07Recruiting
Phenytoin for Memory Impairment Secondary to Megestrol [NCT02595723]Phase 421 participants (Actual)Interventional2015-07-31Completed
A Pilot Study on Fertility Conservative Treatment of Atypical Endometrial Hyperplasia in Singapore [NCT05492487]Phase 260 participants (Anticipated)Interventional2020-01-03Recruiting
Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC) [NCT05913427]Phase 280 participants (Anticipated)Interventional2022-06-08Recruiting
A Pilot Study Evaluating Megestrol Acetate Modulation in Advanced Breast Cancer With Positive Hormonal Receptor [NCT03024580]Phase 220 participants (Anticipated)Interventional2017-03-06Recruiting
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial [NCT05255653]Phase 2/Phase 31,615 participants (Anticipated)Interventional2021-11-11Recruiting
A Randomized, Open Label, Single Dose, Cross-over, Phase I Trial to Investigate Safety and Pharmacokinetics of DW-ES(B) and Megace® Under Fasting and Fed Conditions in Healthy Male Volunteers [NCT01456624]Phase 156 participants (Actual)Interventional2011-09-30Completed
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia [NCT04939090]Phase 3360 participants (Anticipated)Interventional2021-10-15Recruiting
Megestrol Acetate Plus LNG-IUS to Megestrol Acetate in Young Women With Early Endometrial Cancer [NCT03241914]Phase 2/Phase 364 participants (Actual)Interventional2017-07-04Completed
Phase II Study of Everolimus Beyond Progression in Postmenopausal Women With Advanced, Hormone Receptor Positive Breast Cancer [NCT02269670]Phase 23 participants (Actual)Interventional2014-11-25Terminated(stopped due to Slow to accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00483327 (3) [back to overview]Toxicity and Tolerability
NCT00483327 (3) [back to overview]Number of Women Who Became Pregnant
NCT00483327 (3) [back to overview]Best Pathologic Responses
NCT00575029 (2) [back to overview]Number of Participants With Adrenal Insufficiency
NCT00575029 (2) [back to overview]Time Required for Recovery From Adrenal Suppression to Normal Adrenal Function
NCT00637572 (11) [back to overview]Change in Mid-arm Circumference
NCT00637572 (11) [back to overview]Change in Hip Circumference
NCT00637572 (11) [back to overview]Change From Baseline in Lean Mass
NCT00637572 (11) [back to overview]Change in Tricep Skinfold
NCT00637572 (11) [back to overview]Change From Baseline in Impedance
NCT00637572 (11) [back to overview]Change From Baseline in Body Fat Mass
NCT00637572 (11) [back to overview]Quality of Life (QoL) Via Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) at Baseline (Day 3) and Week 12 (BACRI)
NCT00637572 (11) [back to overview]Change in Body Weight
NCT00637572 (11) [back to overview]Appetite at Baseline (Day 3) and Week 12
NCT00637572 (11) [back to overview]Change in Waist Circumference
NCT00637572 (11) [back to overview]Change in Total Energy
NCT00729586 (5) [back to overview]Number of Participants and Their Levels of Expression of the Candidate Markers
NCT00729586 (5) [back to overview]Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0
NCT00729586 (5) [back to overview]Duration of Overall Survival (OS)
NCT00729586 (5) [back to overview]Duration of Progression-free Survival (PFS)
NCT00729586 (5) [back to overview]Percentage of Participants With a Confirmed Objective Tumor Response Using RECIST Version 1.0
NCT00910091 (12) [back to overview]Tolerability of BN83495 Based on Dose Interruptions and Reason for Interruptions
NCT00910091 (12) [back to overview]Percentage of Participants With Adverse Event (AE)
NCT00910091 (12) [back to overview]Percentage of Participants >65 Years of Age With No Change or Deterioration, Improvement of <10%, or Improvement of ≥10% on the EuroQoL Score
NCT00910091 (12) [back to overview]Tolerability of BN83495 Based on Length of Exposure
NCT00910091 (12) [back to overview]Progression Free Survival (PFS): Time From Randomisation Until Objective Tumour Progression or Death From Any Cause
NCT00910091 (12) [back to overview]Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died
NCT00910091 (12) [back to overview]Percentage of Participants With Overall Response (OR) Including CR and PR
NCT00910091 (12) [back to overview]Tolerability of BN83495 Based on Cumulative Dose Administered
NCT00910091 (12) [back to overview]Percentage of Participants With First Documentation of Objective Tumour Progression From Randomisation
NCT00910091 (12) [back to overview]Percentage of Participants With Clinical Benefit [Including Completed Response (CR), Partial Response (PR), and Stable Disease (SD)] ≥12 Weeks
NCT00910091 (12) [back to overview]Overall Survival (OS)
NCT00910091 (12) [back to overview]Duration of Response (DR) in Responders
NCT01237327 (5) [back to overview]Objective Response Rate (ORR)
NCT01237327 (5) [back to overview]Overall Survival
NCT01237327 (5) [back to overview]Time to Treatment Failure (TTF)
NCT01237327 (5) [back to overview]Time to Tumor Progression (TTP)
NCT01237327 (5) [back to overview]Duration of Response (DR)
NCT01968317 (4) [back to overview]Cumulative CR Rates Within 16 Weeks
NCT01968317 (4) [back to overview]Cumulative CR Rates Within 32 Weeks
NCT01968317 (4) [back to overview]Pregnancy Rate
NCT01968317 (4) [back to overview]Recurrence Rate
NCT02595723 (1) [back to overview]Rey Auditory Verbal Learning Test (RAVLT)
NCT03077698 (3) [back to overview]Overall Survival (OS)
NCT03077698 (3) [back to overview]Progression-free Survival (PFS)
NCT03077698 (3) [back to overview]Duration of Stable Disease

Toxicity and Tolerability

Patients with adverse events (AEs) which were possibly, probably, or definitely related to the treatment. AEs were evaluated according to Common Terminology Criteria for Adverse Events (CTCAE) 3. (NCT00483327)
Timeframe: up to 36 months

,
Interventionparticipants (Number)
Weight gainMood alterationsHeadacheThromboembolic eventCarpal tunnel syndromeWeaknessVaginal SpottingVaginal PainNauseaInsomniaFatigueAbdominal PainConstipationIncreased AppetiteDepressionBloating
Grade 1 or 29450116164623434
Grade 30021000000000000

[back to top]

Number of Women Who Became Pregnant

(NCT00483327)
Timeframe: up to 3 years after the treatment for each patient

Interventionparticipants (Number)
Megestrol Acetate3

[back to top]

Best Pathologic Responses

Patients are evaluated every 12 weeks while on treatment. The response is evaluated by endometrial biopsy or dilation and curettage (D&C)/hysteroscopy. Complete response (CR) is defined as endometrial sampling is read as normal or proliferative endometrium. Partial response (PR) is defined as the biopsy sample has changed on the endometrial evaluation scale by at least one level towards normal. Stable disease (SD) is defined as no change in pathology between the index and follow-up sample. Progressive disease (PD) is defined the follow-up sample has changed towards neoplasia on the endometrial evaluation scale by at least one level or imaging is concerning for myometrial invasion or extrauterine disease such that conservative management is no longer medically appropriate. (NCT00483327)
Timeframe: up to 24 months

Interventionparticipants (Number)
Pathologic CRUnconfirmed CRPRSDPD
Megestrol Acetate174612

[back to top]

Number of Participants With Adrenal Insufficiency

Number of participants with adrenal insufficiency after treatment with megestrol acetate assessed by ACTH stimulated cortisol levels less than normal (21 ug/dl) measured weekly for 8 weeks or when adrenal insufficiency is clinically encountered (NCT00575029)
Timeframe: stimulated acth stimulated cortisol levels weekly for 8 weeks or until adrenal insufficiency is encountered

Interventionparticipants (Number)
Megestrol Acetate7

[back to top]

Time Required for Recovery From Adrenal Suppression to Normal Adrenal Function

the number of weeks required for participants to recover from adrenal suppression as assessed by a normal ACTH stimulation test (cortisol level >21 mcg/dl) (NCT00575029)
Timeframe: weekly for up to 6 weeks

Interventionweeks (Number)
participant 1participant 2participant 3participant 4participant 5participant 6participant 7
Megestrol Acetate6222222

[back to top]

Change in Mid-arm Circumference

(NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventioncm (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion-0.6
Megestrol Acetate Oral Suspension Micronized Formulation1.1

[back to top]

Change in Hip Circumference

(NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventioncm (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion2.5
Megestrol Acetate Oral Suspension Micronized Formulation1.8

[back to top]

Change From Baseline in Lean Mass

(NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventionkg (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion2.1
Megestrol Acetate Oral Suspension Micronized Formulation1.3

[back to top]

Change in Tricep Skinfold

(NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventioncm (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion1.0
Megestrol Acetate Oral Suspension Micronized Formulation1.5

[back to top]

Change From Baseline in Impedance

Electrical impedance is a method for body composition assessment. The procedure involves sending a small current through the body and measuring the resistance in ohm. High resistance is associated with smaller amounts of fat-free mass. Smaller resistance is associated with large amounts of fat-free mass. (NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventionohms (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion21.6
Megestrol Acetate Oral Suspension Micronized Formulation12.2

[back to top]

Change From Baseline in Body Fat Mass

(NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventionkg (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion3.2
Megestrol Acetate Oral Suspension Micronized Formulation2.2

[back to top]

Quality of Life (QoL) Via Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) at Baseline (Day 3) and Week 12 (BACRI)

The BACRI instrument is used to measure the benefit of weight gain treatment provided to anorexic patients on health related quality of life aspects. The scale is composed of 9 subscales (0 to 10 [worse to better]). The response was captured on a VAS scale in cm. The total BACRI score is the sum with a minimum score 0=worse and maximum score 90=better. These subscales are: change in weight impacting health; concern about weight; appearance change; change feeling of appearance; change in appetite; enjoy eating; overall feeling; benefit of treatment; and quality of life. (NCT00637572)
Timeframe: Baseline (Day 3) to Week 12

,
Interventioncm (Mean)
Baseline (Day 3)Week 12
Megestrol Acetate Oral Suspension Micronized Formulation50.165.6
Megestrol Acetate Oral Suspension Nanocrystal Dispersion52.367.6

[back to top]

Change in Body Weight

Weight gain in adult HIV positive subjects who have weight loss with AIDS related wasting within the first 12 weeks of treatment (NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

,
Interventionkg (Mean)
OverallMaleFemale
Megestrol Acetate Oral Suspension Micronized Formulation3.53.53.5
Megestrol Acetate Oral Suspension Nanocrystal Dispersion5.47.02.3

[back to top]

Appetite at Baseline (Day 3) and Week 12

"Appetite was assessed via visual analogue scale (VAS) as part of the Bristol-Myers Anorexia/Cachexia Recovery Instrument (BACRI) (Question 5 only). The question was To what extent has your appetite changed since the start of treatment? The response was captured on a VAS scale in cm with a range from 0 ( much worse) to 10 (much better)." (NCT00637572)
Timeframe: Baseline (Day 3) to Week 12

,
Interventioncm (Mean)
Baseline Day 3Week 12
Megestrol Acetate Oral Suspension Micronized Formulation5.88.0
Megestrol Acetate Oral Suspension Nanocrystal Dispersion6.18.4

[back to top]

Change in Waist Circumference

(NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventioncm (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion7.1
Megestrol Acetate Oral Suspension Micronized Formulation5.4

[back to top]

Change in Total Energy

Food intake was quantified by the 24-hour recall food diary (NCT00637572)
Timeframe: Baseline (Day 1) to Week 12

Interventionkcal (Mean)
Megestrol Acetate Oral Suspension Nanocrystal Dispersion215.9
Megestrol Acetate Oral Suspension Micronized Formulation150.6

[back to top]

Number of Participants and Their Levels of Expression of the Candidate Markers

The levels of expression of the candidate markers measured prior to study treatment are tabulated. The expressions being tabulated include immunohistochemical expression of hormone receptors. The hormone receptors are estrogen receptor positive, progesterone receptors-A, progesterone receptor-B, PAKT Positive and PTEN Positive. The associations between the immunohistochemical expression of these biomarkers and between these biomarkers and treatment, outcome or clinical characteristics are reported for future investigation. (NCT00729586)
Timeframe: Baseline

Interventionparticipants (Number)
Estrogen Receptor PositiveProgesterone Receptor PositiveProgesterone Receptor B PositivePAKT PositivePTEN Positive
Receptor Analysis2030351130

[back to top]

Incidence of Adverse Effects (Grade 3 or Higher) as Assessed by Common Terminology Criteria for Adverse Events Version 3.0

Number of participants with a maximum grade of 3 or higher during the treatment period. (NCT00729586)
Timeframe: Assessed every 6 weeks while on treatment, 30 days after the last cycle of treatment.

InterventionParticipants (Count of Participants)
Arm 1: Temsirolimus29
Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus15

[back to top]

Duration of Overall Survival (OS)

Overall survival is defined as the duration of time from study entry to time of death or the date of last contact. (NCT00729586)
Timeframe: Every 6 weeks during treatment, then every 3 months for one year.

Interventionmonths (Median)
Arm 1: Temsirolimus13.3
Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus9.6

[back to top]

Duration of Progression-free Survival (PFS)

Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions assessed radiographically and 50% increase if the only target lesion is a solitary pelvic mass measured by physical exam, or unequivocal progression of a non-target lesion, or the appearance of new lesions. (NCT00729586)
Timeframe: Radiologic tumor evaluations at baseline and every six weeks for the first 24 weeks and then repeated every 12 weeks until disease progression. Repeat after treatment discontinuation if patient was taken off study for reasons other than progression.

Interventionmonths (Median)
Arm 1: Temsirolimus5.6
Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus4.2

[back to top]

Percentage of Participants With a Confirmed Objective Tumor Response Using RECIST Version 1.0

RECIST 1.0 defines complete response as the disappearance of all target lesions and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart. Partial response is defined as at least a 30% decrease in the sum of longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be no unequivocal progression of non-target lesions and no new lesions. Documentation by two disease assessments at least 4 weeks apart is required. In the case where the ONLY target lesion is a solitary pelvic mass measured by physical exam, which is not radiographically measurable, a 50% decrease in the LD is required. These patients will have their response classified according to the definitions stated above. Complete and partial responses are included in the objective tumor response rate. (NCT00729586)
Timeframe: Radiologic tumor evaluations at baseline and every 6 weeks for the first 24 weeks; then repeated every 12 weeks until disease progression. Repeat after treatment discontinuation if patient was taken off study for reasons other than progression.

Interventionpercentage of participants (Number)
Arm 1: Temsirolimus22
Arm 2: Megestrol Acetate+Tamoxifen+ Temsirolimus14.3

[back to top]

Tolerability of BN83495 Based on Dose Interruptions and Reason for Interruptions

Percentage of participants who had dose interruptions and reason for interruptions as AE, study treatment forgotten, and other reasons. (NCT00910091)
Timeframe: Up to 2 years

,
InterventionPercentage of participants (Number)
Dose InterruptionsReason for Interruptions (AE)Reason for Interruptions (Treatment forgotten)Reason for Interruptions (Other)
Arm A: BN83495 40 mg27.816.70.013.9
Arm B: MA 160 mg34.58.68.620.0

[back to top]

Percentage of Participants With Adverse Event (AE)

Grade 1: Mild, Grade 2: Moderate, Grade 3: Severe, Grade 4: Life threatening/disabling and Grade 5: Death (NCT00910091)
Timeframe: Up to Day 28 follow-up

,
InterventionPercentage of subjects (Number)
Any AEsAny Treatment Emergent AEs (TEAEs)Intensity of TEAEs - Grade 5Intensity of TEAEs - Grade 4Intensity of TEAEs - Grade 3Intensity of TEAEs - Grade 2Intensity of TEAEs - Grade 1Intensity of TEAEs - MissingCausality of TEAEs - RelatedCausality of TEAEs - Not relatedTEAEs Leading to WithdrawalTEAEs Leading to DeathSerious Adverse Events (SAEs)
Arm A: BN83495 40 mg88.988.92.85.622.263.980.65.655.677.88.32.825.0
Arm B: MA 160 mg82.982.92.90.025.745.774.30.037.177.12.92.917.1

[back to top]

Percentage of Participants >65 Years of Age With No Change or Deterioration, Improvement of <10%, or Improvement of ≥10% on the EuroQoL Score

EuroQoL (Quality of Life)-5 Dimensions (EQ-5D) is a participant answered questionnaire scoring 5 dimensions: Mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D total score ranges from 0 (worst health state) to 1 (perfect health state) and 1 reflects the best outcome. (NCT00910091)
Timeframe: Up to week 32

,
InterventionPercentage of participants (Number)
No Change or Deterioration at week 2No Change or Deterioration at week 4No Change or Deterioration at week 8No Change or Deterioration at week 16No Change or Deterioration at week 24No Change or Deterioration at week 32Improvement of <10% at week 2Improvement of <10% at week 4Improvement of <10% at week 8Improvement of <10% at week 16Improvement of <10% at week 24Improvement of <10% at week 32Improvement of ≥10% at week 2Improvement of ≥10% at week 4Improvement of ≥10% at week 8Improvement of ≥10% at week 16Improvement of ≥10% at week 24Improvement of ≥10% at week 32
Arm A: BN83495 40 mg54.254.225.025.016.716.70.04.24.20.00.08.320.816.716.712.512.50.0
Arm B: MA 160 mg50.061.150.050.033.322.25.65.65.60.05.65.65.616.716.75.65.65.6

[back to top]

Tolerability of BN83495 Based on Length of Exposure

Length of exposure includes interruptions. (NCT00910091)
Timeframe: Up to 2 years

InterventionWeek (Mean)
Arm A: BN83495 40 mg34.94
Arm B: MA 160 mg55.20

[back to top]

Progression Free Survival (PFS): Time From Randomisation Until Objective Tumour Progression or Death From Any Cause

(NCT00910091)
Timeframe: Up to 2 years

InterventionWeeks (Median)
Arm A: BN83495 40 mg16.14
Arm B: MA 160 mg40.14

[back to top]

Percentage of Women With Advanced or Recurrent Endometrial Cancer Who Have Neither Progressed Nor Died

Subject continuation in the study and Response Evaluation Criteria in Solid Tumours (RECIST) assessment has been based on investigator assessment and not on central review. The 6 month timepoint is defined as the treatment start date +183 days (26 weeks). (NCT00910091)
Timeframe: Up to 6 months

InterventionPercentage of subjects (Number)
Arm A: BN83495 40 mg36.1
Arm B: MA 160 mg54.1

[back to top]

Percentage of Participants With Overall Response (OR) Including CR and PR

(NCT00910091)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Mean)
Arm A: BN83495 40 mg3
Arm B: MA 160 mg11

[back to top]

Tolerability of BN83495 Based on Cumulative Dose Administered

Cumulative dose is the actual total dose administered. (NCT00910091)
Timeframe: Up to 2 years

Interventionmg (Mean)
Arm A: BN83495 40 mg9452.22
Arm B: MA 160 mg60703.03

[back to top]

Percentage of Participants With First Documentation of Objective Tumour Progression From Randomisation

(NCT00910091)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Mean)
Arm A: BN83495 40 mg30
Arm B: MA 160 mg24

[back to top]

Percentage of Participants With Clinical Benefit [Including Completed Response (CR), Partial Response (PR), and Stable Disease (SD)] ≥12 Weeks

"CR: Disappearance of all known disease & no new sites / disease related symptoms confirmed at least 12 weeks after initial documentation. Disappearance of all non-target lesions. Normalization of tumor marker level confirmed at least 12 weeks after initial documentation.~PR: Minimum 30% decrease in sum of the longest diameters of target lesions, taking as a reference the baseline sum of the longest diameters confirmed at least 12 weeks after initial documentation. PR is also recorded when all measurable disease has completely disappeared, but a non-measurable component (i.e., ascites) is still present but not progressing. As well as persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above normal limits.~RECIST defines SD for target lesions as neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, no occurrence of progression disease for non-target lesions, and no new lesions." (NCT00910091)
Timeframe: Up to 2 years

InterventionPercentage of Participants (Mean)
Arm A: BN83495 40 mg13
Arm B: MA 160 mg19

[back to top]

Overall Survival (OS)

OS is defined as the time from the date of enrollment to the date of death due to any cause. (NCT00910091)
Timeframe: At 2 years

InterventionWeeks (Median)
Arm A: BN83495 40 mg63.43
Arm B: MA 160 mgNA

[back to top]

Duration of Response (DR) in Responders

DR is defined as period from the time that measurement criteria are first met for CR or PR until first date of documented Progressive Disease (PD) or death. DR was assessed in participants with a best overall response of CR or PR. (NCT00910091)
Timeframe: At 2 years

InterventionWeeks (Median)
Arm A: BN83495 40 mgNA
Arm B: MA 160 mg105.14

[back to top]

Objective Response Rate (ORR)

Percentage of participants achieving an objective response (OR) defined as complete response (CR) or partial response (PR) out of the total number of participants randomized in each treatment group (NCT01237327)
Timeframe: Every 12 weeks up to 6 years

Interventionpercentage of participants (Number)
Exemestane23.3
Megestrol Acetate12.2

[back to top]

Overall Survival

Overall survival in months measured from date of starting treatment in core study to date of death for any reason. (NCT01237327)
Timeframe: Every 12 weeks up to 6 years

Interventionmonths (Median)
Exemestane29.2
Megestrol Acetate16.3

[back to top]

Time to Treatment Failure (TTF)

TTF = time between first day of study treatment and date of diagnosis of progression, withdrawal from study treatment for any reason, administration of other antitumor treatment, or death from any cause, whichever was the earliest event. (NCT01237327)
Timeframe: Every 12 weeks up to 6 years

Interventionmonths (Median)
Exemestane6.0
Megestrol Acetate3.7

[back to top]

Time to Tumor Progression (TTP)

TTP = time between first day of study treatment and date of documented disease progression, or date of tumor-related death in the absence of previously documented progressive disease (PD). PD defined as a 25% or greater increase in size of 1 or more lesions compared to smallest previous assessment, or appearance of new lesion, or unequivocal worsening of bone lesions, or progression of nonevaluable lesions. (NCT01237327)
Timeframe: Every 12 weeks up to 6 years

Interventionmonths (Median)
Exemestane6.0
Megestrol Acetate3.7

[back to top]

Duration of Response (DR)

Duration of objective response (complete response [CR] or partial response [PR]) calculated from date objective response was first documented to date of progressive disease. For subjects proceeding from PR to CR, the onset of PR was taken as the onset of objective response. (NCT01237327)
Timeframe: Every 12 weeks up to 6 years

Interventionmonths (Median)
Exemestane12.9
Megestrol Acetate35.4

[back to top]

Cumulative CR Rates Within 16 Weeks

"The primary objective was to determine whether metformin plus MA would be associated with a higher CR rate at 3 months of treatment compared with MA alone. However, for patients who eventually underwent the first and second hysteroscopies for endometrium evaluation within 16 weeks of the treatment, the cumulative CR rates within 16 weeks (16w-CR) were analysed as first end point instead of the CR rate at 3 months.~Complete response was defined as the reversion of AEH/EEC to proliferative or secretory endometrium in pathology." (NCT01968317)
Timeframe: 16 weeks after initial treatment

InterventionParticipants (Count of Participants)
Megestrol Acetate and Metformin23
Megestrol Acetate12

[back to top]

Cumulative CR Rates Within 32 Weeks

One of the secondary objectives was between-group comparisons of the cumulative CR rate at 6 months treatment. However, for patients who eventually underwent the second hysteroscopies for endometrium evaluation within 32 weeks of the treatment, the cumulative CR rates within 32 weeks (32w-CR rates) were analysed as secondary end point instead of the CR rate at 6 months. (NCT01968317)
Timeframe: 32 weeks after initial treatment

InterventionParticipants (Count of Participants)
Megestrol Acetate and Metformin52
Megestrol Acetate45

[back to top]

Pregnancy Rate

All patients were followed up till February 2019. The pregnancy rate was calculated only in women who planned for parenthood immediately after achieving CR. (NCT01968317)
Timeframe: through study completion, a median time of 33 months

InterventionParticipants (Count of Participants)
Megestrol Acetate and Metformin19
Megestrol Acetate15

[back to top]

Recurrence Rate

All patients were followed up till February 2019. Statistics of patients who didn't accept hysterectomy and were not lost to follow up were analyzed. (NCT01968317)
Timeframe: through study completion, a median time of 33 months

InterventionParticipants (Count of Participants)
Megestrol Acetate and Metformin7
Megestrol Acetate6

[back to top]

Rey Auditory Verbal Learning Test (RAVLT)

Rey Auditory Verbal Learning Test (RAVLT) is a test of verbal learning and declarative memory. During the test, 15 nouns that are read aloud for 5 consecutive trials. Each trial is followed by a free recall test (participant is asked to recall the words that were just read to them). The sum of correctly recalled words across 5 trials is called the total raw score. The raw scores on the total recall (number of words correct across trials 1-5) are converted to standardized T-scores (Mean=50; SD=10; range 20-100) based on participant age and gender. The scores below are presented as T-scores, with higher scores indicative of better performance. (NCT02595723)
Timeframe: 4 days after intervention administration

InterventionT-scores (Mean)
Phenytoin, Then Megestrol51.89
Placebo, Then Megestrol45.90
Placebo, Then Placebo48.37

[back to top]

Overall Survival (OS)

Once disease progression was documented in Treatment Period 2, subjects returned for the Safety Follow-up Visit four (4) weeks following the last treatment and continued to be followed for an additional 12-month period for overall survival. Overall Survival (OS) was defined as the duration of time from initiation of Treatment Period 2 (Day 0) until the subject's death from any cause. For the purpose of analysis of OS, if a subject is alive at the date of last contact the subject was censored at that date of contact. (NCT03077698)
Timeframe: 12 months

Interventiondays (Number)
001-15-01001-30-01001-39-05001-45-02001-48-01001-01-03001-39-07001-39-08001-43-01001-45-01001-47-03
Sodium Cridanimod & Progestin Therapy529411473541490773239465386438

[back to top]

Progression-free Survival (PFS)

Progressive Disease was assessed using RECIST Guideline (version 1.1) whereas at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Progression-free Survival (PFS) was defined as the duration of time from initiation of Treatment Period 2 (Day 0) until disease progression or death from any cause, whichever occurs first. For the purpose of analysis of PFS, subjects with an unknown response were censored. (NCT03077698)
Timeframe: 24 months

Interventiondays (Number)
001-15-01001-30-01001-39-05001-45-02001-48-01001-01-03001-39-07001-39-08001-43-01001-45-01001-47-03
Sodium Cridanimod & Progestin Therapy1685485851663132886014473

[back to top]

Duration of Stable Disease

Stable Disease (SD) was assessed using RECIST Guideline (version 1.1) whereas neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Duration of Stable Disease was defined as the duration of time from initiation of Treatment Period 2 (Day 0) until the criteria for disease progression were first met. For the purpose of analysis of Duration of SD, subjects who died before documented progressive disease were censored. (NCT03077698)
Timeframe: 24 months

Interventiondays (Number)
001-15-01001-48-01001-45-01
Sodium Cridanimod & Progestin Therapy168166144

[back to top]